On this page
Quick Reference
Overview and Recommendations
Background
- •Hypothyroidism represents a critical failure of the hypothalamic-pituitary-thyroid (HPT) axis to maintain adequate circulating levels of thyroxine (T4) and triiodothyronine (T3), leading to a systemic metabolic deceleration.
- •Primary hypothyroidism accounts for >99% of cases and is characterized by intrinsic thyroid dysfunction, typically resulting from autoimmune destruction ( ) or iatrogenic loss (post-thyroidectomy or radioactive iodine therapy).
- •The prevalence of the condition ranges from 4% to 8% in the general population, but incidence rises sharply with age, reaching up to 18% in women over 60 years old.
- •Iatrogenic and drug-induced causes are major modifiable risk factors; notably, carries a high incidence of hypothyroidism (NNH = 22 over 10 years), and causes dysfunction in approximately 20% of users via the Wolff-Chaikoff effect.
- •Prognostic stakes are high in specific populations, as untreated maternal hypothyroidism increases the risk of pregnancy loss (OR 1.90) and impaired fetal neurodevelopment, while overt disease in the elderly increases all-cause mortality by 25%.
Evaluation
- •Suspect hypothyroidism in patients presenting with insidious onset of fatigue, cold intolerance, modest weight gain (2–5 kg), constipation, and dry skin.
- •Examine for the most specific physical sign: the delayed relaxation phase of deep tendon reflexes (Woltman's sign), which correlates with the severity of the metabolic deficit.
- •Order a serum TSH as the first-line screening test; because the relationship between TSH and FT4 is inverse-logarithmic, TSH is the most sensitive indicator of primary thyroid status.
- •Confirm the diagnosis with paired TSH and Free T4 (FT4) levels to differentiate between primary (High TSH, Low FT4) and central (Low/Normal TSH, Low FT4) etiologies.
- •Measure Thyroid Peroxidase Antibodies (TPOAb) to confirm an autoimmune etiology; positivity predicts a higher rate of progression from subclinical to overt disease.
- •Evaluate for secondary complications such as hyponatremia (Na < 135 mmol/L), hypercholesterolemia, and macrocytic anemia, which are common metabolic signatures of the disease.
- •Identify 'Red Flags' for , including altered mental status, hypothermia (<35.5°C), bradycardia, and respiratory failure (FVC < 15 mL/kg).
- •Perform a pituitary MRI in all confirmed cases of central hypothyroidism to exclude macroadenomas or infiltrative diseases of the sella turcica.
- •Screen for co-existing autoimmune conditions, particularly and Addison's disease, as autoimmune thyroiditis occurs in nearly 50% of patients with adrenal insufficiency.
Management
- •Initiate (LT4) monotherapy as the standard of care at a weight-based dose of 1.6 μg/kg/day (ideal body weight) for healthy, non-elderly adults.
- •Start at a conservative dose of 12.5–25 μg daily in patients over age 65 or those with known coronary artery disease to avoid precipitating myocardial ischemia or arrhythmias.
- •Administer LT4 on an empty stomach, ideally 30–60 minutes before breakfast or 3 hours after the last meal, to ensure optimal absorption.
- •Separate LT4 administration from interfering substances (calcium carbonate, ferrous sulfate, proton pump inhibitors) by at least 4 hours.
- •Titrate the dose every 6–8 weeks based on serum TSH levels, aiming for a target range of 0.4–4.0 mIU/L in most non-pregnant adults.
- •Increase LT4 requirements by 25–50% immediately upon confirmation of pregnancy, aiming for a TSH < 2.5 mIU/L in the first trimester.
- •Treat subclinical hypothyroidism (SCH) when TSH is > 10 mIU/L or if the patient is symptomatic with TPOAb positivity and TSH > 4.5 mIU/L.
- •Manage with immediate IV 100 mg every 8 hours followed by an IV loading dose of 200–400 μg.
- •Avoid using desiccated thyroid extract (DTE) as first-line therapy due to its high T3:T4 ratio, which may cause supraphysiological T3 levels and cardiotoxicity.
- •Monitor patients with central hypothyroidism using FT4 levels rather than TSH, aiming for an FT4 in the upper half of the reference range.
- •Refer to endocrinology for refractory cases, pregnancy, suspected central hypothyroidism, or when cardiac comorbidities complicate titration.
Board Review — High Yield
- •Woltman's Sign — Delayed relaxation phase of deep tendon reflexes; highly specific for hypothyroidism.
- •Wolff-Chaikoff Effect — Autoregulatory phenomenon where high iodine levels (e.g., amiodarone) inhibit thyroid hormone synthesis.
- •Myxedema Coma Triad — Altered mental status, hypothermia, and a precipitating event (e.g., infection, cold).
- •Subclinical Hypothyroidism — Elevated TSH with a normal Free T4; treat if TSH > 10 or in pregnancy.
- •Central Hypothyroidism — Low or 'inappropriately normal' TSH with a low Free T4; requires pituitary imaging.
- •Van Wyk-Grumbach Syndrome — Precocious puberty and multicystic ovaries caused by severe primary hypothyroidism in children.
- •Levothyroxine Absorption — Impaired by calcium, iron, PPIs, and celiac disease; requires acidic gastric environment.
- •HPT Axis in Pregnancy — TSH targets are lower (<2.5 mIU/L) and LT4 requirements increase by ~30% by the 4th-6th week.
Deep Dive — Evidence Details
Definition, Classification and Axis Nomenclature
- ▸Hypothyroidism is classified by the anatomical site of axis disruption: primary (thyroid), secondary (pituitary), or tertiary (hypothalamus).
- ▸Subclinical hypothyroidism is defined by an elevated TSH in the presence of a normal free T4, whereas overt disease requires a subnormal free T4.
- ▸Diagnostic thresholds for TSH are dynamic and must be adjusted for pregnancy, age, and the presence of thyroid antibodies.
Hypothyroidism is a clinical syndrome resulting from a deficiency of thyroid hormones or, rarely, their impaired action at the peripheral tissue level, leading to a generalized slowing of metabolic processes [20]D5. It represents a critical perturbation of the hypothalamic-pituitary-thyroid (HPT) axis, where the failure to maintain adequate circulating levels of thyroxine (T4) and triiodothyronine (T3) results in multisystemic dysfunction [12]B2c[20]D5. The condition is primarily defined by biochemical parameters, as clinical manifestations range from life-threatening emergencies to entirely asymptomatic states [20]D5[21]D5. Hypothyroidism is a major global health concern and remains the most common pregnancy-related thyroid disorder, affecting 3% to 5% of all pregnancies [19]D5.
Synonyms and Abbreviations
- Primary Hypothyroidism: Thyroid gland failure (most common).
- Central Hypothyroidism: Failure of the pituitary (secondary) or hypothalamus (tertiary).
- Subclinical Hypothyroidism: Mild thyroid failure; isolated elevation of TSH with normal FT4 [21]D5.
- (MC): Decompensated, life-threatening hypothyroidism [12]B2c.
- Hashimoto’s Thyroiditis (HT): Chronic autoimmune thyroiditis [10]B3b.
- (CH): Thyroid deficiency present at birth [11]C4.
- MCT8 Deficiency: Allan-Herndon-Dudley syndrome; a rare form of peripheral resistance [6]B3b.
Axis-Based Classification
Classification is fundamentally determined by the anatomical site of the defect within the HPT axis. Primary hypothyroidism accounts for >99% of cases and is characterized by intrinsic thyroid gland dysfunction, resulting in low T4 and a compensatory rise in thyroid-stimulating hormone (TSH) [20]D5. Central hypothyroidism occurs when the pituitary gland (secondary) fails to secrete adequate TSH or the hypothalamus (tertiary) fails to secrete thyrotropin-releasing hormone (TRH) [4]B2a[18]C4. In central cases, TSH is typically low or "inappropriately normal" in the setting of low T4 [28]C4. Rare peripheral hypothyroidism involves defects in thyroid hormone transport (e.g., MCT8 deficiency) or end-organ resistance [6]B3b.
Severity and Biochemical Staging
The distinction between overt and subclinical disease is based on the statistical reference range of TSH, typically using an upper limit of 4.0–5.0 mIU/L, though this threshold is debated for older adults and pregnant populations [16]D5[19]D5.
| Stage | TSH Level | Free T4 (FT4) | Clinical Context |
|---|---|---|---|
| Overt Primary | Elevated (>10 mIU/L) | Low | Symptomatic; high risk of CV complications [20]D5 |
| Subclinical (Mild) | Elevated (Upper limit to 10) | Normal | Often asymptomatic; risk of progression [21]D5 |
| Central | Low or Inappropriately Normal | Low | Associated with other pituitary deficiencies [4]B2a |
| Myxedema Coma | Usually very high (Primary) | Severely Low | Decompensated; altered mental status; hypothermia [12]B2c |
Special Clinical Variants
Specific physiological states require distinct diagnostic nomenclature. Congenital hypothyroidism is classified by the presence or absence of a gland (Gland-in-situ vs. dysgenesis), which predicts the likelihood of finding a genetic mutation via next-generation sequencing [11]C4. In pregnancy, the definition shifts to pregnancy-specific TSH ranges, often using thresholds of >2.5 mIU/L in the first trimester and >3.0 mIU/L thereafter to identify subclinical disease [19]D5. Intrathoracic goiter is classified as primary (ectopic tissue) or secondary (retrosternal extension of a cervical goiter), with the latter being far more common (99% of cases) [7]D5.
Pearl: Hypothyroidism is a biochemical diagnosis where the site of axis failure—primary (thyroid) versus central (pituitary/hypothalamus)—is distinguished by the TSH response to low circulating T4 [20]D5[28]C4.
| Type | TSH | Free T4 | Primary Site of Pathology |
|---|---|---|---|
| Primary | High | Low | Thyroid Gland |
| Secondary | Low/Normal | Low | Anterior Pituitary |
| Tertiary | Low/Normal | Low | Hypothalamus |
| Subclinical | High | Normal | Thyroid Gland (Early failure) |
| Resistance | High | High | Peripheral Receptors |
Axis Physiology, Pathophysiology and Biochemical Signature
- ▸Primary hypothyroidism is characterized by a Th1-mediated inflammatory response and CXC chemokine production (CXCL10) leading to follicular destruction.
- ▸Resistance to Thyroid Hormone Alpha (RTHα) presents with tissue-specific hypothyroidism despite high-normal T3 and normal TSH due to dominant-negative mutations in the THRA gene.
- ▸Hyponatremia in hypothyroidism is primarily driven by decreased cardiac output and elevated ADH levels, impairing free water clearance.
Disruption of the hypothalamic-pituitary-thyroid (HPT) axis occurs when structural or functional lesions impair the homeostatic feedback loop, leading to a failure in maintaining systemic euthyroidism. The axis operates via a classic negative feedback mechanism where thyrotropin-releasing hormone (TRH) from the hypothalamus stimulates the anterior pituitary to secrete thyroid-stimulating hormone (TSH), which in turn drives the thyroid gland to synthesize and release thyroxine (T4) and triiodothyronine (T3) [61]D5.
Molecular Mechanisms of Hormone Synthesis and Action
Thyroid hormone synthesis is a complex process requiring the integration of iodine transport, thyroglobulin (TG) iodination, and enzymatic coupling. While TG is the primary precursor, evidence from biallelic TG mutation models suggests that minimal T4/T3 synthesis can occur via alternative pathways, though it is insufficient to prevent frank hypothyroidism without massive compensatory goitrogenesis [51]D5. Once released, T4 acts largely as a prohormone, converted to the biologically active T3 by type 1 and type 2 deiodinases (DIO1, DIO2) [57]D5[61]D5.
At the cellular level, T3 exerts its effects through nuclear thyroid hormone receptors (TR), primarily TRα and TRβ. TRα1 is the dominant isoform in the heart, bone, and central nervous system, while TRβ1 is highly expressed in the liver and hypothalamus [42]D5[61]D5. Pathogenic variants in the THRA gene result in Resistance to Thyroid Hormone Alpha (RTHα), a condition characterized by tissue-specific hypothyroidism (growth retardation, skeletal dysplasia, and constipation) despite near-normal serum TSH and T4 levels [47]C4[63]C4. In these patients, high-dose (LT4) at 1.75 µg/kg may be required to overcome receptor insensitivity and improve quality of life [67]C4.
Pathogenesis of Primary Hypothyroidism
Primary hypothyroidism arises from direct thyroidal failure, most commonly due to autoimmune destruction or iatrogenic loss. In , the recruitment of Th1 lymphocytes leads to the production of interferon-γ (IFN-γ), which stimulates thyroid follicular cells to secrete CXC chemokines (CXCL9, CXCL10, CXCL11) [44]D5. This inflammatory milieu facilitates the infiltration of T-cells and the production of thyroid peroxidase (TPO) and thyroglobulin (TG) antibodies [33]A1a[48]D5.
- Autoimmune Destruction: Chronic lymphocytic infiltration leads to follicular atrophy and fibrosis [44]D5.
- Iatrogenic Loss: Total or radioactive iodine (RAI) therapy for Graves' disease results in a predictable decline in T4, often necessitating early prophylactic LT4 to prevent quality-of-life deterioration [30]A1b[31]A1a.
- Iodine-Induced Dysfunction: Excess iodine (e.g., from ) can trigger the Wolff-Chaikoff effect, where high intrathyroidal iodine concentrations acutely inhibit organification, leading to hypothyroidism in susceptible individuals [36]D5[48]D5.
Central and Peripheral Axis Disruption
Central hypothyroidism occurs when the pituitary (secondary) or hypothalamus (tertiary) fails to produce adequate TSH or TRH. This is frequently observed in multiglandular syndromes like , where hypothalamic dysfunction leads to a constellation of deficiencies including TSH, growth hormone, and gonadotropins [58]D5.
Peripheral resistance or impaired sensitivity to thyroid hormones represents a distinct biochemical signature. The Thyroid Feedback Quantile-based Index (TFQI) has been proposed to quantify this insensitivity, which is increasingly linked to metabolic syndrome and type 2 diabetes [46]B2c[60]D5. Furthermore, certain medications can suppress TSH without altering thyroid status; for instance, has been shown to lower TSH levels in hypothyroid patients on stable LT4 doses without changing free T4 levels [38]C4.
Biochemical Signatures and Systemic Impact
The biochemical hallmark of primary hypothyroidism is an elevated TSH with a low free T4. However, specific clinical scenarios alter this pattern:
| Condition | TSH | Free T4 | Free T3 | Mechanism |
|---|---|---|---|---|
| Primary Hypothyroidism | High | Low | Low/Normal | Thyroidal failure; T3 preserved by DIO2 up-regulation [61]D5 |
| Central Hypothyroidism | Low/Normal | Low | Low | Pituitary/Hypothalamic failure [58]D5 |
| RTHα | Normal | Low-Normal | High-Normal | THRA mutation; high T3/T4 ratio [63]C4[67]C4 |
| Subclinical Hypothyroidism | High | Normal | Normal | Early compensatory phase [29]A1c |
Systemic consequences of these biochemical shifts include reduced cardiac output and increased systemic vascular resistance, which can impair free water excretion and lead to hyponatremia (Na < 135 mmol/L) [54]D5[57]D5. In severe cases, the lack of T3-mediated signaling in the hypothalamus disrupts thermoregulation, primarily through TRα1 pathways, contributing to the hypothermia seen in [52]D5.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Selenium in Hashimoto's | Supplementation reduces TPOAb titers [33]A1a[48]D5. | No clear clinical benefit on thyroid function or QoL [33]A1a. | Moderate | Routine use is not universally recommended by ATA. |
| Subclinical Hypothyroidism in Pregnancy | Treat if TSH > 2.5-4.0 mIU/L to prevent adverse outcomes [29]A1c[59]D5. | Treatment benefit is uncertain in TPOAb-negative women with mild TSH elevation [29]A1c. | High | Thresholds for treatment remain a major focus of ATA 2026 updates. |
Pearl: The biochemical signature of hypothyroidism is defined by the site of failure: primary disease manifests with a TSH elevation that precedes T4 decline, whereas central disease and RTHα require careful interpretation of "normal" TSH in the context of low or discordant free hormone levels [47]C4[58]D5[63]C4.
| Pattern | TSH | Free T4 | Clinical Context |
|---|---|---|---|
| Primary (Overt) | Elevated | Low | Hashimoto's, Post-ablative |
| Primary (Subclinical) | Elevated | Normal | Early autoimmune disease |
| Central | Low or inappropriately Normal | Low | Pituitary adenoma, Sheehan syndrome |
| Amiodarone-Induced (Type 2) | Variable | Low | Direct cytotoxicity/Wolff-Chaikoff [36]D5 |
Epidemiology, Etiology and Risk Factors
- ▸The global prevalence of hypothyroidism is 4-8%, rising to nearly 18% in elderly women.
- ▸Lithium therapy carries a five-fold increased risk of developing hypothyroidism (OR 5.2).
- ▸Autoimmune thyroiditis is the most frequent etiology in iodine-sufficient regions, while iodine deficiency remains a factor in specific global pockets.
Prevalence of hypothyroidism in the general population ranges from 4% to 8%, with rates as high as 15% to 18% in women over age 60 [111]A1a. In Europe, the prevalence of undiagnosed hypothyroidism is estimated at 5% [72]B2a. While historically iodine deficiency was the primary global driver, chronic autoimmune thyroiditis (Hashimoto's thyroiditis) is now the most common cause in iodine-sufficient regions [100]D5[20]D5. The incidence of (CH) is also rising, with recent data showing rates have more than doubled over the last decade, particularly among preterm infants [116]B2b.
Demographic Distribution and Temporal Trends
Female sex and advancing age are the strongest predictors of thyroid dysfunction. Women are significantly more likely than men to develop both overt and subclinical disease, with a marked increase in incidence from early adolescence through the sixth decade of life [91]B3b[100]D5. Geography remains a critical determinant; in India, hypothyroidism is a major public health challenge with high regional incidence [98]D5, while in China, the implementation of universal salt iodization has shifted the epidemiological profile toward a higher prevalence of subclinical hypothyroidism and autoimmune thyroiditis associated with more-than-adequate iodine intake [95]B2c[99]B2b.
Mechanistic Etiologies
Etiologies are broadly categorized by their impact on the hypothalamic-pituitary-thyroid (HPT) axis:
- Autoimmune: Hashimoto's thyroiditis is characterized by thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TgAb) positivity. TPOAb positivity is a major precursor; individuals with positive antibodies and a TSH >2.5 mU/L are at the highest risk for progression to overt disease [117]B3b[70]A1a.
- Iatrogenic: This includes post- status, radioactive iodine (RAI) therapy for Graves' disease or thyroid cancer, and external beam radiation to the neck [100]D5[112]A1a. Survivors of childhood cancer have a significantly elevated lifetime risk of endocrine disorders due to prior treatments [90]B2b.
- Drug-Induced: (37% iodine by weight) causes dysfunction in ~20% of patients through either the Wolff-Chaikoff effect or direct cytotoxicity [36]D5. Lithium is associated with a high incidence of hypothyroidism (OR 5.2, 95% CI 4.6–5.9; NNH = 22 over 10 years) [89]A1a[102]B3b. Immune Checkpoint Inhibitors (ICPis), such as and , frequently cause thyroiditis or as immune-related adverse events [109]D5[105]A1a.
- Central/Secondary: Central hypothyroidism arises from pituitary or hypothalamic masses, trauma, or genetic mutations such as biallelic POMC variants, which also present with early-onset obesity [101]D5[86]C4.
- Genetic: Rare disorders include MCT8 deficiency (SLC16A2 mutation), which causes cerebral hypothyroidism despite peripheral thyrotoxicosis [6]B3b.
Risk Factors and Comorbidities
Type 1 diabetes (T1D) is strongly associated with autoimmune thyroid disease; approximately 22.8% of T1D patients have a co-existing autoimmune condition, most commonly hypothyroidism [93]B2b. The familial risk of hypothyroidism is also elevated in relatives of patients with T1D (SIR 3.68) [103]B3b. Obesity is another significant risk factor, with a pooled prevalence of hypothyroidism of 10.1% in obese populations [84]A1a.
| Risk Factor | Association (OR/RR) | Evidence Level |
|---|---|---|
| TPOAb Positivity | High risk of progression | 1a [83]A1a[117]B3b |
| Lithium Use | OR 5.2 (95% CI 4.6–5.9) | 1a [89]A1a |
| Type 1 Diabetes | 22.8% prevalence of AD | 2b [93]B2b |
| Obesity (BMI >30) | Prevalence 10.1% | 1a [84]A1a |
| Amiodarone | ~20% of users | 5 [36]D5 |
| Excess Iodine Intake | Increased incidence of SCH | 2b [99]B2b |
Pregnancy-Specific
Gestational thyroid dysfunction is common and often coincides with gestational diabetes [88]A1a. Risk factors for thyroid abnormalities during pregnancy include maternal age, high BMI, and TPOAb positivity [78]A1a. While subclinical hypothyroidism in pregnancy is associated with adverse outcomes, large trials have shown that treatment for subclinical disease (TSH 4.0–10.0 mU/L) does not improve cognitive outcomes in offspring [77]A1b.
Pearl: Hashimoto's thyroiditis is the leading cause of hypothyroidism in iodine-sufficient areas, but iatrogenic causes—particularly lithium (NNH=22) and amiodarone—represent the most common modifiable risk factors in clinical practice [89]A1a[36]D5[100]D5.
| Category | Primary Examples | Mechanism |
|---|---|---|
| Primary (Thyroidal) | Hashimoto's, Iodine deficiency/excess, Iatrogenic (Surgery/RAI) | Direct gland failure |
| Secondary (Central) | Pituitary adenoma, Hypophysitis (ICPi-induced), Trauma | TSH deficiency |
| Drug-Induced | Lithium, Amiodarone, Tyrosine kinase inhibitors | Synthesis inhibition or cytotoxicity |
| Consumptive | Infantile hemangiomas | Excessive Type 3 deiodinase activity |
Clinical Presentation
- ▸Symptoms are highly non-specific; fatigue, cold intolerance, and weight gain are common but have low positive predictive value in isolation.
- ▸Central hypothyroidism must be suspected when low thyroid hormone levels occur without a compensatory rise in TSH, often accompanied by other pituitary axis failures.
- ▸Myxedema coma is a clinical diagnosis of exclusion in patients with severe hypothyroidism, hypothermia, and altered mental status.
Clinical manifestations of thyroid hormone deficiency span a broad spectrum, ranging from an asymptomatic state to life-threatening multisystem failure [20]D5[100]D5. Because thyroid receptors are ubiquitously expressed, the phenotype is characterized by a generalized slowing of metabolic processes and the accumulation of glycosaminoglycans in the interstitial space [20]D5[101]D5. Symptoms often develop insidiously over months or years, leading many patients to attribute early signs like fatigue or weight gain to aging or lifestyle factors [100]D5[120]B3b.
Presenting Symptoms
Fatigue and lethargy are the most frequent presenting complaints, occurring in nearly all symptomatic patients [20]D5[100]D5. Patients typically report a distinct cold intolerance, often requiring extra layers of clothing in environments others find comfortable [20]D5. Weight gain is common but usually modest (typically 2–5 kg) and primarily reflects fluid retention rather than adipose accumulation [100]D5[133]D5. Dermatologic changes include dry, coarse skin and brittle hair; in advanced cases, non-pitting edema (myxedema) develops due to dermal deposition of hyaluronic acid [20]D5[100]D5. motility is reduced, leading to constipation, while vocal cord edema may produce a characteristic hoarseness [20]D5.
Neurological and Musculoskeletal Findings
Cognitive slowing, often described as "brain fog," manifests as impaired memory and poor concentration [100]D5. On physical examination, the most specific sign is the delayed relaxation phase of deep tendon reflexes (woltmans sign), most easily elicited at the Achilles tendon [125]C4. Entrapment neuropathies, particularly , occur due to myxedematous infiltration of the flexor retinaculum [134]B2b. Patients may also present with proximal muscle weakness and myalgia, sometimes accompanied by an elevation in serum creatine kinase [100]D5.
Phenotypic Variants
The clinical presentation varies significantly based on the etiology and the patient's life stage.
| Variant | Key Features | Frequency |
|---|---|---|
| Primary (Hashimoto's) | Goiter (early) or atrophic gland (late); often associated with other autoimmune diseases [100]D5[121]D5. | Most common |
| Central (Secondary) | Often lacks goiter; associated with other pituitary deficiencies (e.g., adrenal insufficiency, hypogonadism) [101]D5[123]C4. | Rare |
| Congenital | Prolonged jaundice, large fontanelles, umbilical hernia, and macroglossia; often asymptomatic at birth due to maternal T4 [119]A1c[132]C4. | 1:2000–4000 births |
| Iatrogenic | Rapid onset of symptoms following or radioactive iodine; may be transient after [130]B2b. | Common post-op |
| Drug-Induced | -induced (Type 2) or immune checkpoint inhibitor-induced thyroiditis; often preceded by a transient thyrotoxic phase [36]D5[122]C4. | Variable |
Red Flags and Emergencies
Severe, untreated hypothyroidism can progress to , a state of decompensated metabolism [12]B2c[126]C4. Critical findings requiring urgent intervention include altered mental status (ranging from lethargy to coma), hypothermia (often <35.5°C), and bradycardia [12]B2c. Respiratory compromise may manifest as chronic alveolar hypoventilation or obstructive sleep apnea, even in non-obese patients [141]C4. FVC < 15 mL/kg or significant hypercapnia on arterial blood gas should prompt consideration for mechanical ventilation [12]B2c[141]C4. Hyponatremia is a frequent metabolic complication, driven by impaired free water excretion and elevated ADH levels [54]D5.
Atypical Presentations
In pediatric populations, long-standing primary hypothyroidism can trigger Van Wyk-Grumbach syndrome, characterized by isosexual , delayed bone age, and multicystic ovaries [39]C4. Conversely, adults may present with isolated psychiatric symptoms ("myxedema madness") or unexplained serous effusions (pericardial, pleural, or peritoneal) [12]B2c[100]D5. In rare cases of infiltrative disease, such as Riedel’s thyroiditis, the presentation is dominated by a "stony hard" neck mass and obstructive symptoms like dysphagia or airway compression [129]D5.
Pearl: The most specific physical finding for hypothyroidism is the delayed relaxation of deep tendon reflexes, which correlates with the severity of the metabolic deficit even when other symptoms are non-specific [125]C4.
| System | Clinical Findings |
|---|---|
| Metabolic | Cold intolerance, modest weight gain, hypothermia |
| Neurological | Delayed reflex relaxation, carpal tunnel syndrome, cognitive slowing |
| Dermatologic | Dry skin, brittle hair, non-pitting edema (myxedema), loss of outer third of eyebrows |
| Cardiovascular | Bradycardia, narrowed pulse pressure, pericardial effusion |
| Gastrointestinal | Constipation, macroglossia, ascites (rare) |
| Reproductive | Menorrhagia, oligomenorrhea, galactorrhea (due to TRH-induced prolactin rise) |
Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
- ▸TSH is the most sensitive marker for primary hypothyroidism due to the inverse-logarithmic relationship with FT4.
- ▸Central hypothyroidism requires a low FT4 for diagnosis, as TSH may be low, normal, or even slightly elevated.
- ▸TPOAb testing is the primary tool for identifying autoimmune etiology and assessing the risk of progression in subclinical disease.
Biochemical confirmation of thyroid hormone deficiency relies on the interpretation of paired serum thyroid-stimulating hormone (TSH) and free thyroxine (FT4) concentrations [100]D5[143]A1c. Because the relationship between TSH and FT4 is inverse-logarithmic, small changes in FT4 result in exponential changes in TSH, making TSH the most sensitive indicator of primary thyroid status [20]D5[69]A1c. Diagnosis is established when these parameters fall outside of statistically defined reference intervals (RI), though these ranges are increasingly scrutinized for their lack of age- and physiological-specificity [20]D5[151]B2c.
Laboratory Studies and Biochemical Signature
First-line evaluation requires a simultaneous TSH and FT4 to differentiate between primary and central etiologies. In primary hypothyroidism, the biochemical signature is an elevated TSH with a low FT4 (overt) or a normal FT4 (subclinical) [69]A1c[144]B2a. Conversely, central hypothyroidism is characterized by a low, inappropriately normal, or slightly elevated TSH in the setting of a low FT4 [101]D5[152]D5.
| Classification | TSH Level | FT4 Level | Clinical Context |
|---|---|---|---|
| Overt Primary | Elevated (typically >10 mIU/L) | Low | Symptomatic; high risk of complications [69]A1c |
| Subclinical Primary | Elevated (4.5–10 mIU/L) | Normal | Often asymptomatic; requires repeat testing [74]B2a[144]B2a |
| Central | Low or Inappropriately Normal | Low | Suggests pituitary/hypothalamic lesion [101]D5 |
| Isolated Hypothyroxinemia | Normal | Low | Common in pregnancy; clinical significance debated [156]D5 |
Immunoassays for FT4 are susceptible to interference from serum binding protein alterations, heterophilic antibodies, or thyroid hormone autoantibodies [157]D5[168]C4. In cases of discordance between clinical status and laboratory results, liquid chromatography-tandem mass spectrometry (LC-MS/MS) or equilibrium dialysis is the gold standard for accurate FT4 measurement [157]D5[168]C4.
Dynamic Testing and Functional Assessment
Dynamic testing is rarely required for primary hypothyroidism but remains essential for evaluating the integrity of the hypothalamic-pituitary-thyroid (HPT) axis in complex cases. In patients with suspected central hypothyroidism, a TRH stimulation test may be utilized, though its use has declined with improved TSH assay sensitivity [101]D5. A blunted or delayed TSH response to TRH suggests pituitary or hypothalamic dysfunction, respectively [101]D5[152]D5. For patients with suspected , a perchlorate discharge test can identify iodine organification defects, where a discharge of >10–15% of radioiodine after potassium perchlorate administration indicates a positive result [152]D5[160]C4.
Localization and Imaging
Anatomic localization is secondary to biochemical confirmation and is primarily used to determine etiology or assess for compressive symptoms.
- Thyroid Ultrasonography: The modality of choice for assessing gland volume and parenchymal texture. In Hashimoto’s thyroiditis, ultrasound typically reveals a diffuse, heterogeneous, hypoechoic pattern with increased vascularity [69]A1c[100]D5.
- Radionuclide Uptake and Scanning: Using Technetium-99m or Iodine-123 is critical in the workup of congenital hypothyroidism to differentiate between thyroid dysgenesis (ectopy or agenesis) and dyshormonogenesis [68]A1c[119]A1c.
- Pituitary MRI: Mandatory in all cases of confirmed central hypothyroidism to exclude macroadenomas, infiltrative diseases, or empty sella syndrome [101]D5[153]B3b.
Diagnostic Algorithm
- Initial Screen: Order serum TSH. If TSH is elevated (>4.5 mIU/L), reflex to FT4 [69]A1c.
- Confirmation: If TSH is 4.5–10 mIU/L with a normal FT4, repeat testing in 1–3 months to exclude transient elevation (e.g., recovery from non-thyroidal illness) [69]A1c[150]D5.
- Etiology Workup: Measure Thyroid Peroxidase Antibodies (TPOAb). Positivity confirms autoimmune etiology and predicts a higher rate of progression from subclinical to overt disease [69]A1c[78]A1a.
- Central Evaluation: If FT4 is low but TSH is not appropriately elevated, evaluate other pituitary axes (ACTH, gonadotropins) and perform a pituitary MRI [101]D5[153]B3b.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Pregnancy TSH Cut-off | Use 2.5 mIU/L in 1st trimester [142]A1c[149]A1c | Use center-specific or modified non-pregnant RI [29]A1c[76]A1a | Moderate | Avoids overdiagnosis in pregnancy |
| Subclinical Treatment | Treat if TSH >10 mIU/L [69]A1c | Observe if age >65–75 and TSH <10 [150]D5 | Strong | Prevents overtreatment in elderly |
Pearl: Diagnosis must never rely on TSH alone in suspected pituitary disease, as a "normal" TSH in the setting of low FT4 is the hallmark of central hypothyroidism [101]D5[152]D5.
| Condition | TSH | FT4 | Primary Mechanism |
|---|---|---|---|
| Primary Hypothyroidism | High | Low | Thyroid gland failure |
| Subclinical Hypothyroidism | High | Normal | Compensated thyroid failure |
| Central Hypothyroidism | Low/Normal | Low | Pituitary/Hypothalamic failure |
| Thyroid Hormone Resistance | High/Normal | High | Receptor insensitivity (THRA/THRB) |
Severity, Staging and Risk Stratification
- ▸Overt hypothyroidism (TSH >10 mIU/L with low fT4) significantly increases all-cause mortality and MACE in patients with ischemic heart disease (RR 1.63).
- ▸A TPOAb threshold of >113.4 IU/mL is a critical predictor for the progression from euthyroidism to clinical hypothyroidism.
- ▸In pregnancy, TSH should be maintained below 2.5–3.0 mIU/L to mitigate risks of neurodevelopmental delay and obstetric complications.
Risk stratification in hypothyroidism relies on biochemical thresholds and the presence of comorbid cardiovascular or metabolic stressors. While the diagnosis is established by paired hormone analysis, the severity of the disease state dictates the urgency of intervention and the intensity of surveillance. This is particularly critical in vulnerable populations, such as pregnant women and neonates, where even mild biochemical deviations can lead to irreversible neurodevelopmental or obstetric complications [29]A1c[119]A1c.
Biochemical Severity and Grading
The clinical spectrum is graded primarily by the degree of thyrotropin (TSH) elevation and the preservation of free thyroxine (fT4) levels. Subclinical hypothyroidism (SCH) is defined by a TSH above the reference range (typically >4.0–4.5 mIU/L) with a normal fT4 [173]B2a. Overt hypothyroidism is characterized by an elevated TSH (often >10 mIU/L) and a subnormal fT4 [172]A1a.
In patients with positive thyroid autoantibodies (TPOAb or TgAb), the risk of progression from euthyroidism to overt disease is significantly higher. A TPOAb cutoff of >113.4 IU/mL has been identified as a high-risk threshold for future onset of hypothyroidism [117]B3b. In the context of Graves' disease treated with radioactive iodine (131I), the occurrence of early transient hypothyroidism (ETH) within the first 6 months serves as a prognostic marker, often preceding permanent hypothyroidism [184]B3b.
Cardiovascular and Metabolic Risk Stratification
Hypothyroidism acts as a significant modifier of cardiovascular risk, necessitating aggressive lipid and rhythm . Overt hypothyroidism is associated with and ; replacement significantly reduces total cholesterol (mean reduction 23.5 mg/dL) and LDL-C (mean reduction 20.5 mg/dL) [172]A1a.
| Risk Category | Clinical Context | Impact/Outcome |
|---|---|---|
| Ischemic Heart Disease (IHD) | Overt Hypothyroidism | Increased all-cause mortality (HR 1.83, 95% CI 1.34–2.50) [170]B2a |
| Heart Failure (HF) | TSH >10 mIU/L | Increased risk of HF events and mortality [57]D5 |
| (AF) | TSH ≥10 mIU/L | HR 2.89 (95% CI 1.05–7.94) for AF in HOCM patients [182]B3b |
| NAFLD/Liver Fibrosis | Primary Hypothyroidism | 2.1-fold increased risk of NAFLD (OR 2.13, 95% CI 1.36–3.35) [79]A1a[174]B2a |
In patients with IHD, hypothyroidism increases the risk of major adverse cardiac events (MACE) by 63% (RR 1.63, 95% CI 1.22–2.18) [170]B2a. For those with heart failure first diagnosed during sepsis, the presence of thyroid dysfunction can complicate the differentiation between systolic dysfunction and heart failure with preserved ejection fraction (HFpEF) [25]B3b.
Risk Stratification in Special Populations
In pregnancy, risk is stratified by TSH thresholds to prevent fetal neurodevelopmental impairment. The American Thyroid Association (ATA) and Endocrine Society recommend a TSH goal of <2.5 mIU/L in the first trimester and <3.0 mIU/L in subsequent trimesters [142]A1c[149]A1c. For preconception, women with TPOAb positivity and a TSH >2.5 mIU/L are at increased risk for progression and may require early levothyroxine initiation [29]A1c.
(CH) requires immediate risk tiering based on the severity of the initial TSH elevation and the presence of a thyroid gland in situ. Severe CH (fT4 <5 pmol/L) requires higher initial doses of levothyroxine (10–15 μg/kg/day) to ensure optimal long-term neurocognitive outcomes [68]A1c[119]A1c.
Non-Thyroidal Illness Syndrome (NTIS)
In the intensive care unit (ICU), risk is stratified by the degree of T3 and T4 suppression. NTIS represents an adaptive or maladaptive response to systemic illness, where low T3 and T4 levels correlate with increased mortality, though causality remains unproven [181]D5. Unlike primary hypothyroidism, TSH in NTIS is typically normal or low-normal, reflecting hypothalamic-pituitary suppression [181]D5.
Controversies and Guideline Disagreement
| Question | Position A (ATA/Endocrine Society) | Position B (NICE/International) | Strength | Implication |
|---|---|---|---|---|
| Treatment of SCH (TSH 4.5–10) | Treat if symptomatic, TPOAb+, or high CVD risk [173]B2a | Observation often preferred in elderly (>65y) [57]D5 | Moderate | Avoids over-treatment in the aged |
| Selenium in Hashimoto's | Not routinely recommended due to lack of long-term benefit [33]A1a | May consider for reducing TPOAb titers in select cases | Low | Supplementation remains common but evidence-weak |
Pearl: Cardiovascular risk in hypothyroidism is non-linear, with TSH levels >10 mIU/L conferring a nearly 2-fold increase in all-cause mortality in patients with pre-existing ischemic heart disease [170]B2a.
| Grade | TSH Level | Free T4 Level | Clinical Action |
|---|---|---|---|
| Subclinical (Mild) | 4.5–10.0 mIU/L | Normal | Monitor; treat if TPOAb+ or symptomatic |
| Subclinical (Severe) | >10.0 mIU/L | Normal | Replacement therapy usually indicated |
| Overt | Elevated (usually >10) | Low | Immediate levothyroxine replacement |
| Central | Low, Normal, or Mildly High | Low | Evaluate other pituitary axes; treat to fT4 target |
Acute Management and Endocrine Emergencies
- ▸Myxedema coma requires immediate IV levothyroxine (200–400 µg) and empiric hydrocortisone (100 mg q8h) to prevent adrenal crisis.
- ▸Active external rewarming must be avoided in hypothermic patients to prevent distributive shock from peripheral vasodilation.
- ▸Iodine-based contrast media and lithium are potent triggers for decompensation in patients with underlying thyroid dysfunction.
Decompensated hypothyroidism, or (MC), represents a rare but life-threatening endocrine emergency characterized by a breakdown in physiological adaptation to chronic thyroid hormone deficiency [12]B2c (2c). While most hypothyroid patients remain clinically stable, acute stressors—such as infection, myocardial infarction, or exposure to iodine-based contrast media (ICM)—can precipitate a rapid decline into multi-organ failure [191]C4 (4). requires immediate intensive care admission, aggressive thyroid hormone replacement, and empiric glucocorticoid coverage to prevent adrenal crisis in the setting of potential polyglandular failure [193]C4 (4).
Step 1: Initial Assessment and Severity Classification
Clinicians must differentiate between severe primary hypothyroidism and true myxedema coma based on the presence of altered mental status and physiological decompensation. The National Inpatient Sample indicates that MC patients have significantly higher mortality rates compared to non-decompensated hypothyroid patients (OR 9.05, 95% CI 6.12–13.38) [12]B2c.
- Identify Precipitating Factors: Screen for sepsis, cold exposure, or recent medication changes (e.g., lithium, , or ICM) [191]C4[192]C4.
- Assess Organ Dysfunction: Evaluate for hypothermia (often <35.5°C), bradycardia, and respiratory failure due to decreased hypercapnic drive [12]B2c.
- Cardiac Evaluation: Perform urgent echocardiography. Severe hypothyroidism is associated with impaired global longitudinal strain (GLS) and pericardial effusions; 11.6% of MC patients exhibit severe left ventricular systolic dysfunction [195]B3b (3b).
Step 2: First-line Intervention (Hormone Replacement and Steroids)
Thyroid hormone replacement must be initiated intravenously to bypass potential malabsorption. Administer 100 mg IV every 8 hours prior to or concurrent with thyroid hormone to avoid precipitating an adrenal crisis if coexisting adrenal insufficiency is present [193]C4.
- (T4) Loading: 200–400 µg IV bolus, followed by 50–100 µg IV daily [12]B2c.
- (T3) Supplementation: Consider adding 5–20 µg IV bolus, followed by 2.5–10 µg every 8 hours. T3 provides a more rapid metabolic onset, which may be critical in severe cases, though it carries a higher risk of precipitating arrhythmias in elderly patients with ischemic heart disease [170]B2a[201]D5.
Step 3: Supportive Care and Metabolic Correction
Correction of metabolic derangements is essential for survival. Hyponatremia in MC is typically dilutional due to impaired free water excretion and requires fluid restriction rather than aggressive saline unless severe hypotension is present [154]D5 (5).
- Passive Rewarming: Use blankets only; active external rewarming is contraindicated as it may cause peripheral vasodilation and worsen circulatory collapse [12]B2c.
- Glucose Management: Monitor for hypoglycemia, which may reflect concomitant growth hormone or ACTH deficiency [178]C4.
- Respiratory Support: Maintain a low threshold for mechanical ventilation in patients with hypercapnia or severe obtundation [12]B2c.
Step 4: Monitoring and Titration
Monitor TSH and free T4 levels every 24–48 hours during the acute phase. Clinical improvement (increased temperature, improved mentation) usually precedes biochemical normalization. In the intensive care unit, clinicians should utilize machine learning-based models or clinical scores to monitor for hypothyroidism-associated delirium (HAD), which is strongly linked to adverse outcomes in the elderly [208]B2c (2c).
Step 5: Resolution and Transition
Transition to oral levothyroxine once the patient is hemodynamically stable and mentation has returned to baseline. The oral dose is typically 1.6 µg/kg/day, though requirements may be lower in the elderly or those with significant cardiac comorbidities [194]D5.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| T4 vs. T4+T3 Combination | ATA/Endocrine Society — Suggests T4 monotherapy is standard, but T3 may be added in severe MC [12]B2c[194]D5 | Emerging Evidence — Suggests T3 is necessary for rapid metabolic recovery due to impaired T4-to-T3 conversion in critical illness [181]D5[185]B2b | Moderate | Clinicians often use combination therapy in the ICU despite lack of large RCTs. |
| Management of NTIS | Standard Practice — Do not treat Non-Thyroidal Illness Syndrome (NTIS) in the ICU [181]D5 | Experimental Views — Some suggest T3 replacement may improve cardiac output in specific subsets [170]B2a | Strong | Routine treatment of NTIS remains contraindicated as it may represent a protective adaptation [181]D5. |
Pearl: Myxedema coma is a clinical, not biochemical, diagnosis; initiate IV levothyroxine and stress-dose glucocorticoids immediately upon suspicion to reduce the 9-fold increase in mortality associated with decompensation [12]B2c[193]C4.
| Drug | Starting Dose | Route | Key Monitoring | Rationale |
|---|---|---|---|---|
| Hydrocortisone | 100 mg q8h | IV | Blood glucose, BP | Prevents adrenal crisis [193]C4 |
| Levothyroxine (T4) | 200–400 µg | IV Bolus | ECG, Free T4 | Restores hormone pool [12]B2c |
| Liothyronine (T3) | 5–20 µg | IV Bolus | Heart rate, Rhythm | Rapid metabolic onset [201]D5 |
| Dextrose 50% | 25–50 mL | IV PRN | Fingerstick glucose | Corrects hypoglycemia [178]C4 |
Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
- ▸LT4 monotherapy is the gold standard, requiring strict adherence to fasting administration or a 15% dose adjustment if taken with food.
- ▸Pregnancy requires immediate dose escalation (25-50%) and tighter TSH targets (<2.5 mIU/L) to optimize fetal neurodevelopment.
- ▸Treatment of subclinical hypothyroidism is mandatory for TSH >10 mIU/L but should be avoided in older adults with TSH <7 mIU/L.
(LT4) monotherapy remains the standard of care for the treatment of hypothyroidism, aiming to restore clinical and biochemical euthyroidism while avoiding the risks of iatrogenic thyrotoxicosis [69]A1c[143]A1c. The therapeutic spine of involves precise titration to a serum thyrotropin (TSH) target, typically within the laboratory-specific reference range (0.4–4.0 mIU/L), though these targets are adjusted based on age, pregnancy status, and comorbidities [69]A1c[223]D5. While LT4 effectively normalizes TSH in most patients, approximately 10–15% of patients reach biochemical targets but report persistent symptoms, driving ongoing investigation into combination therapies and alternative formulations [20]D5[209]A1c.
Step 1: Initial Dosing and Formulation Selection
Initiate weight-based dosing in healthy, non-elderly adults with overt hypothyroidism at 1.6 μg/kg/day (ideal body weight) [69]A1c[143]A1c. In patients with known coronary artery disease or those aged >65 years, start at a lower dose of 12.5–25 μg daily to prevent precipitating myocardial ischemia or arrhythmias [69]A1c[150]D5. The ATA 2014 guidelines recommend LT4 as the first-line preparation due to its long half-life (7 days), low cost, and consistent bioavailability (strong recommendation, high-quality evidence) [143]A1c.
Step 2: Administration and Absorption Optimization
Administer LT4 on an empty stomach, ideally 30–60 minutes before breakfast or 3 hours after the last meal of the day, to ensure maximal absorption [69]A1c[143]A1c. malabsorption is a frequent cause of refractory hypothyroidism; common culprits include H. pylori infection, celiac disease, and atrophic gastritis [225]D5. Furthermore, medications such as proton pump inhibitors, calcium carbonate, and ferrous sulfate can significantly impair LT4 uptake and should be separated by at least 4 hours [69]A1c[225]D5. A 2026 randomized trial suggests that if fasting intake is not feasible, a 15% dose increase may maintain TSH stability during non-fasting (breakfast) administration [210]A1b (1b).
Step 3: Monitoring and Titration
Measure serum TSH 6–8 weeks after initiation or any dose change [69]A1c[143]A1c. Once the target TSH is achieved, monitoring frequency may be reduced to 6–12 months [69]A1c. In patients with central hypothyroidism, TSH is not a reliable marker; instead, clinicians must titrate LT4 to maintain free T4 (fT4) in the upper half of the reference range [101]D5[221]D5. For patients with type 2 diabetes, be aware that can lower TSH levels without altering fT4, potentially masking undertreatment [187]B2b (2b).
Step 4: Management of Subclinical Disease
Treat subclinical hypothyroidism (SCH) when TSH is >10 mIU/L due to the increased risk of heart failure and cardiovascular mortality [21]D5[69]A1c. For TSH levels between the upper limit of normal and 10 mIU/L, treatment is individualized based on symptoms, TPO antibody positivity, or cardiovascular risk factors [21]D5[143]A1c. However, the TRUST trial (N=737) demonstrated that in adults aged ≥65 years with TSH 4.6–19.9 mIU/L, LT4 did not improve hypothyroid symptoms or quality of life (HR for benefit not significant) [213]A1b (1b).
Step 5: Special Populations and Pregnancy
In pregnancy, LT4 requirements increase by 25–50%, often as early as the 4th–6th week of gestation [142]A1c[146]D5. The Endocrine Society recommends a TSH target of <2.5 mIU/L in the first trimester and <3.0 mIU/L thereafter [142]A1c. For women with SCH and TPO antibodies, LT4 treatment reduces the risk of pregnancy loss (RR 0.48, 95% CI 0.25–0.92; NNT = 9) [70]A1a[215]A1a. In , initiate LT4 at 10–15 μg/kg/day within the first 2 weeks of life to prevent irreversible neurodevelopmental delay [68]A1c[119]A1c.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| LT4 + LT3 Combination | ATA 2014: LT4 monotherapy is the standard; combination therapy is not routinely recommended [143]A1c. | ETA/BTA 2021: Consider a trial of LT4+LT3 in patients with persistent symptoms despite biochemical euthyroidism [209]A1c. | Moderate | Clinicians may offer combination therapy as an N-of-1 trial for symptomatic patients despite lack of RCT superiority [71]A1b[212]A1a. |
| TSH Targets in Elderly | ATA/AACE: Target the lower half of the reference range if tolerated [69]A1c. | Endocrine Society 2025: Suggest a higher TSH target (up to 7-8 mIU/L) in those >70-80 years to avoid overtreatment [150]D5. | Moderate | Higher TSH targets in the elderly reduce the risk of iatrogenic and osteoporosis. |
| Selenium in Hashimoto's | Some Reviews: Suggest selenium reduces TPOAb titers [33]A1a[48]D5. | Cochrane/ATA: Insufficient evidence to recommend selenium for clinical outcomes [33]A1a[143]A1c. | Mild | Selenium is not standard of care but widely used as a supplement. |
What NOT to Do
- Do NOT use desiccated thyroid extract (DTE) as first-line therapy; while some patients prefer it, the high T3:T4 ratio (1:4.2) often leads to supraphysiological T3 levels and potential cardiotoxicity [143]A1c[212]A1a.
- Do NOT adjust LT4 doses based on T3 levels alone, as T3 remains normal until late-stage hypothyroidism [69]A1c.
- Do NOT routinely treat subclinical hypothyroidism in patients >65 years with TSH <7 mIU/L unless specific indications exist [150]D5[213]A1b.
Pearl: Titrate LT4 to a TSH target of 0.4–4.0 mIU/L in most adults, but prioritize weight-based dosing (1.6 μg/kg) in the young and conservative initiation (12.5–25 μg) in the elderly to balance symptom relief with cardiovascular safety [69]A1c[143]A1c[150]D5.
| Drug | Starting Dose | Target / Max Dose | Renal Adjustment | Hepatic Adjustment | Key Monitoring |
|---|---|---|---|---|---|
| Levothyroxine (LT4) | 1.6 μg/kg/day (Adults); 12.5-25 μg (Elderly/CAD) | Titrate to TSH 0.4–4.0 mIU/L | No adjustment | No adjustment | TSH every 6-8 weeks until stable |
| Liothyronine (LT3) | 5 μg daily (as adjunct) | Titrate to avoid T3 peaks | No adjustment | No adjustment | Serum Total T3, Heart Rate |
| Desiccated Thyroid (DTE) | 30 mg daily | Titrate to TSH; not first-line | No adjustment | No adjustment | TSH, Total T3 |
Multiglandular Syndromes, Genetic Context and Co-Axis Effects
- ▸Autoimmune thyroid disease is the most common comorbidity in Addison disease, affecting nearly half of all patients.
- ▸Genetic syndromes like Down syndrome and Prader-Willi syndrome require routine thyroid screening due to high rates of non-autoimmune and hypothalamic hypothyroidism.
- ▸Hypothyroidism significantly alters renal filtration and hemostatic balance, typically predisposing patients to a bleeding diathesis.
Genetic syndromes and systemic comorbidities frequently dictate the clinical trajectory of thyroid dysfunction, as hypothyroidism rarely exists in isolation within these complex phenotypes. The identification of thyroid hormone deficiency must prompt immediate surveillance for adjacent endocrine failures, particularly in monogenic autoimmune disorders and neurodevelopmental syndromes where co-axis perturbations are the rule rather than the exception [159]D5[245]D5.
Monogenic and Polyendocrine Autoimmune Syndromes
Autoimmune thyroid disease is the most frequent comorbidity in patients with autoimmune Addison disease (AAD), affecting 48% of this population [246]B2b. Among those with AAD and thyroid involvement, 42% present with autoimmune hypothyroidism, which is often subclinical (73%) at the time of adrenal diagnosis [246]B2b. This clustering is most pronounced in monogenic forms of autoimmunity, which typically manifest at a younger age than polygenic variants [159]D5.
- APS-1 (APECED): Caused by biallelic mutations in the AIRE gene, this syndrome is defined by the triad of mucocutaneous candidiasis, , and adrenocortical failure [148]C4[252]C4. While hypothyroidism is not part of the diagnostic dyad, it occurs as a frequent secondary component due to progressive endocrine gland destruction [148]C4.
- : Hemizygous FOXP3 mutations lead to immune dysregulation, polyendocrinopathy, and enteropathy. In cohorts with permanent neonatal diabetes, FOXP3 mutations were identified in 60% of male subjects who also exhibited additional immune-related disorders, including autoimmune thyroiditis [94]C4.
Neurodevelopmental and Ciliopathy-Related Hypothyroidism
Thyroid dysfunction in the context of intellectual disability often stems from shared genetic pathways governing hypothalamic development or ciliary function.
- (DS): Individuals with DS exhibit a high prevalence of both congenital and subclinical hypothyroidism (SH) [239]B2c. Epigenome-wide association studies show aberrant DNA methylation in thyroid development genes, such as TG and DIO2, in DS individuals [239]B2c. In a 5-year prospective study, 37% of DS children with SH were positive for thyroid autoantibodies, while the remainder had non-autoimmune SH, suggesting a dual etiology of immune dysregulation and developmental dysgenesis [251]B2b.
- (PWS): This hypothalamic disorder, caused by loss of paternally expressed genes on 15q11-13, results in a complex endocrine trajectory [245]D5. Hypothyroidism is a core feature alongside growth hormone deficiency and hypogonadotropic hypogonadism, necessitating a comprehensive endocrine workup to manage the transition from neonatal anorexia to childhood hyperphagia [58]D5[245]D5.
- Rare Genetic Clusters: Syndromes such as HRD (hypoparathyroidism-retardation-dysmorphism), caused by TBCE mutations, and GLIS3 deficiency present with severe, multi-organ endocrine failure [238]C4[244]C4. GLIS3 mutations specifically cause a phenotype of neonatal diabetes and severe hypothyroidism despite normal thyroid anatomy [244]C4.
Cross-Axis Metabolic and Systemic Effects
Thyroid hormones exert profound influence on the metabolic homeostasis of the liver, kidneys, and cardiovascular system, creating a bidirectional relationship where organ failure exacerbates thyroid dysfunction [247]D5.
- Hepato-Thyroid Axis: Hypothyroidism contributes to the development of metabolic dysfunction-associated steatotic liver disease (MASLD) and [247]D5. Conversely, hepatic dysfunction reduces the peripheral conversion of T4 to T3, leading to an "intrahepatic" hypothyroid state [247]D5.
- Renal and Hemostatic Impact: Hypothyroidism is associated with decreased glomerular filtration rates and impaired water excretion [154]D5. It also induces a mild-to-moderate bleeding tendency, whereas most other endocrine disorders favor a thrombotic state [250]D5.
- Metabolic Syndrome and Diabetes: Subclinical hypothyroidism is longitudinally associated with incident metabolic syndrome, particularly in women [240]B2b. Impaired sensitivity to thyroid hormones, measured by the Thyroid Feedback Quantile-based Index (TFQI), is strongly associated with increased diabetes prevalence and obesity [46]B2c[60]D5.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Universal Screening in Pregnancy | Universal screening for all pregnant women to prevent neurodevelopmental delay [163]A1a. | Targeted case-finding based on risk factors (e.g., DS, T1DM) [163]A1a. | Moderate | Cochrane reviews find insufficient evidence that universal screening improves infant outcomes [163]A1a. |
| NTIS Treatment | Non-thyroidal illness syndrome (NTIS) in the ICU is a protective adaptation; do not treat [181]D5. | NTIS in ischemic heart disease (IHD) predicts mortality; consider replacement [170]B2a. | Low | Meta-analysis shows NTIS in IHD increases all-cause mortality (RR 2.46) [170]B2a. |
Pearl: In patients with autoimmune Addison disease, the prevalence of autoimmune thyroiditis is approximately 48%, necessitating lifelong biochemical surveillance of the TSH even if the patient is initially euthyroid [246]B2b.
| Syndrome | Genetic Basis | Key Endocrine Features | Thyroid Pathology |
|---|---|---|---|
| APS-1 | AIRE (21q22.3) | Hypoparathyroidism, Addison's | Autoimmune destruction [148]C4 |
| IPEX | FOXP3 (Xp11.23) | Neonatal Diabetes, Enteropathy | Early-onset Autoimmunity [94]C4 |
| Down Syndrome | Trisomy 21 | T1DM, Dyslipidemia | Dysgenesis & Autoimmunity [239]B2c |
| PWS | 15q11-13 (paternal) | GH deficiency, Hypogonadism | Hypothalamic dysfunction [58]D5 |
| BLTS | NKX2-1 | Chorea, Lung disease | Primary Hypothyroidism [242]C4 |
Complications and Long-term Sequelae
- ▸Overt hypothyroidism in patients ≥60 years is associated with a 15% increase in cardiovascular mortality (RR 1.15).
- ▸Hypothyroidism is a significant risk factor for NAFLD (OR 1.52) and accelerated progression of chronic kidney disease.
- ▸Suboptimal replacement (TSH >10 mIU/L) in surgical patients increases the risk of postoperative MACE and long-term mortality.
Chronic thyroid hormone deficiency induces systemic metabolic deceleration and structural remodeling that persists if replacement is suboptimal. In the elderly, overt hypothyroidism is associated with increased all-cause mortality (RR 1.25, 95% CI 1.13–1.39) and cardiovascular mortality (RR 1.15, 95% CI 1.01–1.32) [256]A1a. Even subclinical hypothyroidism (SCH) carries a significant burden; a meta-analysis of 7 prospective cohorts demonstrated a pooled hazard ratio (HR) for all-cause mortality of 1.41 (95% CI 1.12–1.79) [260]A1a. The risk is particularly pronounced in patients with pre-existing ischemic heart disease, where hypothyroidism significantly increases the incidence of major adverse cardiac events (MACE) [170]B2a.
Cardiovascular and Metabolic Sequelae
Cardiovascular complications arise from decreased myocardial contractility, increased systemic vascular resistance, and accelerated atherosclerosis [57]D5[263]D5. Hypothyroidism is strongly associated with nonalcoholic fatty liver disease (NAFLD), with a pooled odds ratio of 1.52 (95% CI 1.24–1.87) [79]A1a. This metabolic derangement extends to glucose homeostasis; impaired sensitivity to thyroid hormones, as measured by the Thyroid Feedback Quantile-based Index (TFQI), is independently associated with a higher prevalence of diabetes and metabolic syndrome [46]B2c. In patients undergoing ( ), preoperative hypothyroidism is linked to worse long-term outcomes, particularly if TSH levels remain poorly controlled [273]B3b.
Respiratory and Renal Monitoring
Respiratory failure in severe hypothyroidism results from a combination of blunted hypoxic drive, respiratory muscle weakness, and upper airway obstruction due to macroglossia [80]D5. Patients with a Forced Vital Capacity (FVC) < 50% predicted or those exhibiting hypercapnia require intensive monitoring for impending respiratory failure [80]D5. Renal function is similarly compromised through reduced glomerular filtration rates and impaired water excretion, which can exacerbate hyponatremia [262]B3b[263]D5. In patients with chronic kidney disease (CKD), untreated hypothyroidism accelerates the progression to renal failure and increases mortality [262]B3b.
Neurocognitive and Reproductive Impact
Long-term cognitive decline and dementia are significant risks in chronic hypothyroidism [73]B3b. Observational data suggest that standard (LT4) monotherapy may not fully mitigate these risks, whereas therapies containing (T3) have been associated with a reduced risk of dementia and mortality in some cohorts [73]B3b. Reproductive complications include menstrual irregularities (typically oligomenorrhea), subfertility, and increased risk of miscarriage [266]D5. In pregnant women, even euthyroid autoimmune thyroid disease (positive TPOAb) is associated with preterm delivery and impaired fetal neurodevelopment [59]D5[156]D5.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Treatment of SCH in adults >65 | Treat if TSH >10 mIU/L to reduce CVD risk [150]D5[21]D5 | Observe if TSH <7–10 mIU/L as mortality benefit is unproven [97]D5[150]D5 | Moderate | Avoids overtreatment in the elderly |
| DTE vs. LT4 Monotherapy | LT4 is the standard of care due to stability [label, 258] | Desiccated Thyroid Extract (DTE) may improve QoL in select patients [258]A1a | Low | Patient preference vs. biochemical consistency |
Pearl: Chronic hypothyroidism increases all-cause mortality by approximately 25% in the elderly, necessitating strict TSH targeting to mitigate cardiovascular and metabolic decay [256]A1a[260]A1a.
| Complication | Frequency | Prevention/Surveillance | Management |
|---|---|---|---|
| Myxedema Coma | Rare (<1%) | Adherence to LT4; avoid triggers | IV Levothyroxine 200-400 µg + Hydrocortisone [12]B2c |
| NAFLD/MAFLD | High (20-30%) | Annual LFTs; Lipid panel | Weight loss; optimized LT4 replacement [79]A1a[8]B2c |
| Hyponatremia | Common in severe cases | Monitor Serum Na+ in acute illness | Fluid restriction; thyroid hormone replacement [263]D5 |
| DVT/PE | Increased risk | Prophylaxis in hospitalized patients | LMWH (e.g., Enoxaparin 40 mg SC daily) |
| Respiratory Failure | Rare (Severe) | FVC monitoring; Sleep study | CPAP or mechanical ventilation if hypercapnic [80]D5 |
Prognosis, Natural History, Special Populations and Prevention
- ▸Overt hypothyroidism in pregnancy significantly increases risks of preterm birth, pre-eclampsia, and pregnancy loss (OR 1.90).
- ▸Congenital hypothyroidism treatment must be initiated within 14 days of birth to prevent permanent neurodevelopmental delay.
- ▸In patients over 75, subclinical hypothyroidism may not require treatment as it is not consistently linked to mortality or cognitive decline.
Prognosis for patients with primary hypothyroidism is excellent with appropriate (LT4) replacement, though the natural history varies significantly by etiology and life stage [69]A1c[100]D5. While most cases of are permanent, transient forms occur in or following [142]A1c[149]A1c. In the elderly, untreated overt disease is associated with increased cardiovascular morbidity, whereas the impact of subclinical hypothyroidism (SCH) on mortality in patients over age 60 is less clear, with some meta-analyses showing no significant increase in all-cause mortality (RR 1.04, 95% CI 0.97–1.12) [256]A1a.
Pregnancy and Reproductive Health
Maternal thyroid hormone is critical for fetal neurodevelopment, particularly before the fetal thyroid becomes functional at 18–20 weeks of gestation [220]B2b. Untreated overt hypothyroidism increases the risk of pregnancy loss, preterm birth, and impaired offspring IQ [142]A1c[215]A1a. The American Thyroid Association (ATA) recommends a TSH treatment threshold of >2.5 mU/L in the first trimester if TPO antibodies are present, or >10.0 mU/L regardless of antibody status [29]A1c[149]A1c.
| Outcome | Association with Untreated Hypothyroidism | Evidence Level |
|---|---|---|
| Pregnancy Loss | Increased risk (OR 1.90, 95% CI 1.21–2.98) | 1a [215]A1a |
| Pre-eclampsia | Increased risk (OR 1.47, 95% CI 1.15–1.89) | 2a [219]B2a |
| Gestational Diabetes | Positive association with higher TSH | 1a [88]A1a |
| Offspring IQ | Potential reduction if maternal TSH is elevated | 1b [77]A1b[214]A1b |
Despite these associations, the TABLET and T4LIFE trials demonstrated that LT4 treatment in euthyroid women with thyroid antibodies does not improve live birth rates [222]D5. Furthermore, treating mild SCH (TSH <10 mU/L) during pregnancy has not consistently shown improvements in childhood cognitive function at age 3 or 5 years [77]A1b[214]A1b.
Pediatric and
Congenital hypothyroidism (CH) occurs in approximately 1 in 2,000 to 4,000 live births and requires immediate intervention to prevent irreversible intellectual disability [68]A1c[119]A1c. Newborn screening programs have largely eliminated the severe neurodevelopmental sequelae of CH in developed nations [37]D5. Treatment with LT4 (10–15 μg/kg/day) should ideally begin within the first 2 weeks of life [68]A1c[119]A1c. While most CH is permanent due to thyroid dysgenesis or dyshormonogenesis (e.g., DUOX2 or TPO mutations), approximately 30% of cases with a gland in situ may be transient, requiring re-evaluation at age 3 [68]A1c[276]C4[278]C4.
Geriatric Considerations and Cognitive Health
in the elderly requires a "start low, go slow" approach to avoid precipitating arrhythmias or myocardial ischemia [69]A1c[224]D5. In patients over 75 years, SCH is often not associated with cognitive decline, and some evidence suggests that mildly elevated TSH in the very elderly may be a normal physiological adaptation [74]B2a[256]A1a. However, in younger cohorts (<75 years), SCH has been linked to an increased risk of cognitive impairment and dementia [74]B2a. Recent observational data suggest that therapies containing (T3) might be associated with a reduced risk of dementia compared to LT4 monotherapy, though randomized controlled trials are needed to confirm this [73]B3b.
Prevention and Screening
Prevention focuses on adequate iodine intake, as iodine deficiency remains the leading cause of preventable intellectual disability worldwide [100]D5[267]A1a. Conversely, excessive iodine (e.g., from or contrast media) can induce hypothyroidism via the Wolff-Chaikoff effect [107]D5. Screening is generally targeted rather than universal. The ATA and Endocrine Society recommend screening in pregnant women over age 30, those with a family history of thyroid disease, or those with co-existing autoimmune conditions like Type 1 Diabetes Mellitus [29]A1c[93]B2b[142]A1c.
Controversies and Guideline Disagreement
| Question | ATA Position [29]A1c[149]A1c | ESC/NICE Position [222]D5 | Strength | Implication |
|---|---|---|---|---|
| Universal Pregnancy Screening | Targeted case-finding preferred | Insufficient evidence for universal | Moderate | Varies by local institutional policy |
| TSH Threshold for Pregnancy | >2.5 mU/L (if TPOAb+) | Often >4.0 mU/L or local ref | Low | Affects number of women treated |
Pearl: In pregnancy, the goal of LT4 therapy is to maintain TSH within the lower half of the trimester-specific reference range to optimize feto-maternal outcomes [29]A1c[142]A1c.
References
- [1]
Yeap BB, Alfonso H, Chubb SA et al.. “Higher free thyroxine levels predict increased incidence of dementia in older men: the Health in Men Study.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22977271 ↗
L2RCTCited in: Definition, Classification and Axis Nomenclature - [2]
Dong AC, Stagnaro-Green A. “Differences in Diagnostic Criteria Mask the True Prevalence of Thyroid Disease in Pregnancy: A Systematic Review and Meta-Analysis.” Thyroid : official journal of the American Thyroid Association (2018). PMID: 30444186 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature - [3]
Khan SR, Bano A, Wakkee M et al.. “The association of autoimmune thyroid disease (AITD) with psoriatic disease: a prospective cohort study, systematic review and meta-analysis.” European journal of endocrinology (2017). PMID: 28747386 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature - [4]
Kokshoorn NE, Wassenaar MJ, Biermasz NR et al.. “Hypopituitarism following traumatic brain injury: prevalence is affected by the use of different dynamic tests and different normal values.” European journal of endocrinology (2009). PMID: 19783619 ↗
L2SR_OBSCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification - [5]
Andersen SL, Andersen S, Vestergaard P et al.. “Maternal Thyroid Function in Early Pregnancy and Child Neurodevelopmental Disorders: A Danish Nationwide Case-Cohort Study.” Thyroid : official journal of the American Thyroid Association (2018). PMID: 29584590 ↗
L2COHORTCited in: Definition, Classification and Axis Nomenclature - [6]
Groeneweg S, van Geest FS, Abacı A et al.. “Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study.” The lancet. Diabetes & endocrinology (2020). PMID: 32559475 ↗
L3COHORTCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [7]
Hegedüs L, Bonnema SJ. “Approach to management of the patient with primary or secondary intrathoracic goiter.” The Journal of clinical endocrinology and metabolism (2010). PMID: 21131536 ↗
L5CASE_REPORTCited in: Definition, Classification and Axis Nomenclature - [8]
Chen YL, Tian S, Wu J et al.. “Impact of Thyroid Function on the Prevalence and Mortality of Metabolic Dysfunction-Associated Fatty Liver Disease.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36637992 ↗
L2OTHERCited in: Definition, Classification and Axis Nomenclature, Complications and Long-term Sequelae - [9]
Wang V, Walsh JA, Zell J et al.. “Autoimmune Disease is Increased in Women With Primary Ovarian Insufficiency.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39607709 ↗
L3OTHERCited in: Definition, Classification and Axis Nomenclature - [10]
Zhao W, Kang Q, Qian F et al.. “Convolutional Neural Network-Based Computer-Assisted Diagnosis of Hashimoto's Thyroiditis on Ultrasound.” The Journal of clinical endocrinology and metabolism (2022). PMID: 34907442 ↗
L3OTHERCited in: Definition, Classification and Axis Nomenclature - [11]
Levaillant L, Bouhours-Nouet N, Illouz F et al.. “The Severity of Congenital Hypothyroidism With Gland-In-Situ Predicts Molecular Yield by Targeted Next-Generation Sequencing.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36884306 ↗
L4OTHERCited in: Definition, Classification and Axis Nomenclature - [12]
Chen DH, Hurtado CR, Chang P et al.. “Clinical Features and Outcomes of Myxedema Coma in Patients Hospitalized for Hypothyroidism: Analysis of the United States National Inpatient Sample.” Thyroid : official journal of the American Thyroid Association (2024). PMID: 38279788 ↗
L2OTHERCited in: Definition, Classification and Axis Nomenclature, Clinical Presentation, Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae - [13]
Singh B, Bakian AV, Newman M et al.. “The Association Between Thyrotropin and Clinically Relevant Depression: A Retrospective Cross-Sectional Study.” Thyroid : official journal of the American Thyroid Association (2025). PMID: 39909475 ↗
L3OTHERCited in: Definition, Classification and Axis Nomenclature - [14]
Perros P, Nagy EV, Papini E et al.. “Hypothyroidism and Somatization: Results from E-Mode Patient Self-Assessment of Thyroid Therapy, a Cross-Sectional, International Online Patient Survey.” Thyroid : official journal of the American Thyroid Association (2023). PMID: 37134204 ↗
L4OTHERCited in: Definition, Classification and Axis Nomenclature - [15]
Barrio M, Raeburn CD, McIntyre R et al.. “Computer-Assisted Levothyroxine Dose Selection for the Treatment of Postoperative Hypothyroidism.” Thyroid : official journal of the American Thyroid Association (2023). PMID: 37084246 ↗
L3OTHERCited in: Definition, Classification and Axis Nomenclature - [16]
Brabant G, Beck-Peccoz P, Jarzab B et al.. “Is there a need to redefine the upper normal limit of TSH?” European journal of endocrinology (2006). PMID: 16645008 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature - [17]
Daskas N, Sharples P, Likeman M et al.. “Growth hormone secretion, fatigue and quality of life after childhood traumatic brain injury.” European journal of endocrinology (2019). PMID: 31319378 ↗
L2OTHERCited in: Definition, Classification and Axis Nomenclature - [18]
Buurman H, Saeger W. “Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data.” European journal of endocrinology (2006). PMID: 16645024 ↗
L4OTHERCited in: Definition, Classification and Axis Nomenclature - [19]
Teng W, Shan Z, Patil-Sisodia K et al.. “Hypothyroidism in pregnancy.” The lancet. Diabetes & endocrinology (2013). PMID: 24622371 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [20]
Chaker L, Bianco AC, Jonklaas J et al.. “Hypothyroidism.” Lancet (London, England) (2017). PMID: 28336049 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [21]
Cooper DS, Biondi B. “Subclinical thyroid disease.” Lancet (London, England) (2012). PMID: 22273398 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [22]
Wang Z, Li L, Huang P et al.. “Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial.” The lancet. Gastroenterology & hepatology (2025). PMID: 41319673 ↗
L2TRIAL_NONRANDOMCited in: Definition, Classification and Axis Nomenclature - [23]
Zhan H, Yang Z, Liu P et al.. “Risk Factors for Shoulder Stiffness After Rotator Cuff Repair: A Systematic Review and Meta-analysis.” The American journal of sports medicine (2026). PMID: 41731320 ↗
L3SR_OBSCited in: Definition, Classification and Axis Nomenclature - [24]
Harding KB, Peña-Rosas JP, Webster AC et al.. “Iodine supplementation for women during the preconception, pregnancy and postpartum period.” The Cochrane database of systematic reviews (2017). PMID: 28260263 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification - [25]
Pradeep AG, Zubair Z, Jia K et al.. “Phenotypes and Outcomes of Heart Failure First Diagnosed During Sepsis: A Single-Center Retrospective Cohort Study Using ICD-10-Based Subtype Classification.” Journal of clinical medicine (2026). PMID: 42279113 ↗
L3COHORTCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Complications and Long-term Sequelae - [26]
Choi JE, Oh J, Song DK et al.. “Air pollution and risk of autoimmune thyroid diseases in children and adolescents: Findings from a nationwide cohort study in Korea.” Ecotoxicology and environmental safety (2026). PMID: 41601047 ↗
L2COHORTCited in: Definition, Classification and Axis Nomenclature - [27]
. “[Guidelines for the diagnosis and treatment of obstructive sleep apnea in adults (2025)].” Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases (2026). PMID: 41820035 ↗
L1GUIDELINECited in: Definition, Classification and Axis Nomenclature, Axis Physiology, Pathophysiology and Biochemical Signature - [28]
Kopanos S, Knappe UJ, Moeller AS et al.. “Delay in Diagnosis of Thyroid-Stimulating Hormone-Secreting Pituitary Adenomas: Clinical and Endocrinological Profiles from a Retrospective Cohort Study.” Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme (2025). PMID: 41338539 ↗
L4COHORTCited in: Definition, Classification and Axis Nomenclature - [29]
Korevaar TIM, Leung AM, Alexander EK et al.. “American Thyroid Association 2026 Guidelines for Thyroid Disease in Preconception, Pregnancy, and Postpartum.” Thyroid : official journal of the American Thyroid Association (2026). PMID: 42219800 ↗
L1GUIDELINECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Prognosis, Natural History, Special Populations and Prevention - [30]
Taïeb D, Bournaud C, Eberle MC et al.. “Quality of life, clinical outcomes and safety of early prophylactic levothyroxine administration in patients with Graves' hyperthyroidism undergoing radioiodine therapy: a randomized controlled study.” European journal of endocrinology (2016). PMID: 26772985 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [31]
Huynh CN, Pearce JV, Kang L et al.. “Weight Gain After Thyroidectomy: A Systematic Review and Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33106852 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [32]
Smith MR, Saad F, Chowdhury S et al.. “Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.” The New England journal of medicine (2018). PMID: 29420164 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [33]
Huwiler VV, Maissen-Abgottspon S, Stanga Z et al.. “Selenium Supplementation in Patients with Hashimoto Thyroiditis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.” Thyroid : official journal of the American Thyroid Association (2024). PMID: 38243784 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [34]
Ledermann JA, Embleton AC, Raja F et al.. “Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.” Lancet (London, England) (2016). PMID: 27025186 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [35]
Søgaard M, Farkas DK, Ehrenstein V et al.. “Hypothyroidism and hyperthyroidism and breast cancer risk: a nationwide cohort study.” European journal of endocrinology (2016). PMID: 26863886 ↗
L2COHORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [36]
Ylli D, Wartofsky L, Burman KD. “Evaluation and Treatment of Amiodarone-Induced Thyroid Disorders.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33159436 ↗
L5CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [37]
Léger J, Delcour C, Carel JC. “Fetal and Neonatal Thyroid Dysfunction.” The Journal of clinical endocrinology and metabolism (2022). PMID: 34636892 ↗
L5CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [38]
Vigersky RA, Filmore-Nassar A, Glass AR. “Thyrotropin suppression by metformin.” The Journal of clinical endocrinology and metabolism (2005). PMID: 16219720 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [39]
Baranowski E, Högler W. “An unusual presentation of acquired hypothyroidism: the Van Wyk-Grumbach syndrome.” European journal of endocrinology (2011). PMID: 22170796 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Clinical Presentation - [40]
Min L, Vaidya A, Becker C. “Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy.” European journal of endocrinology (2010). PMID: 21088057 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [41]
Stan MN, Toro-Tobon D. “Graves' disease: a new era of pathophysiology-guided therapeutics.” The Journal of clinical endocrinology and metabolism (2026). PMID: 41530911 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [42]
Li L, Song Y, Shi Y et al.. “Thyroid Hormone Receptor-β Agonists in NAFLD Therapy: Possibilities and Challenges.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36746649 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [43]
Kamitani F, Nishioka Y, Nakajima H et al.. “Multiple or Single Endocrine Abnormalities Associated With Immune Checkpoint Inhibitors.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40503677 ↗
L2OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [44]
Fallahi P, Ferrari SM, Ragusa F et al.. “Th1 Chemokines in Autoimmune Endocrine Disorders.” The Journal of clinical endocrinology and metabolism (2020). PMID: 31863667 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [45]
Bezin J, Gouverneur A, Pénichon M et al.. “GLP-1 Receptor Agonists and the Risk of Thyroid Cancer.” Diabetes care (2023). PMID: 36356111 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [46]
Laclaustra M, Moreno-Franco B, Lou-Bonafonte JM et al.. “Impaired Sensitivity to Thyroid Hormones Is Associated With Diabetes and Metabolic Syndrome.” Diabetes care (2018). PMID: 30552134 ↗
L2OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae - [47]
Bochukova E, Schoenmakers N, Agostini M et al.. “A mutation in the thyroid hormone receptor alpha gene.” The New England journal of medicine (2011). PMID: 22168587 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [48]
Hu S, Rayman MP. “Multiple Nutritional Factors and the Risk of Hashimoto's Thyroiditis.” Thyroid : official journal of the American Thyroid Association (2017). PMID: 28290237 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [49]
Samuels MH, Bernstein LJ. “Brain Fog in Hypothyroidism: What Is It, How Is It Measured, and What Can Be Done About It.” Thyroid : official journal of the American Thyroid Association (2022). PMID: 35414261 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [50]
Xiang P, Latif R, Davies TF. “The Thyrotropin Receptor Antibody Reactome Determines Thyroid and Retro-orbital Responsiveness.” Thyroid : official journal of the American Thyroid Association (2025). PMID: 40654270 ↗
L5OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [51]
Young C, Zhang X, Kellogg AP et al.. “Thyroid Hormone Synthesis Without Thyroglobulin.” Thyroid : official journal of the American Thyroid Association (2026). PMID: 41801750 ↗
L5OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [52]
Sentis SC, Dore R, Oelkrug R et al.. “Hypothalamic Thyroid Hormone Receptor α1 Signaling Controls Body Temperature.” Thyroid : official journal of the American Thyroid Association (2024). PMID: 38149585 ↗
L5OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [53]
Daniels GH, Ross DS. “Radioactive Iodine: A Living History.” Thyroid : official journal of the American Thyroid Association (2023). PMID: 37307104 ↗
L5OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [54]
Liamis G, Filippatos TD, Liontos A et al.. “MANAGEMENT OF ENDOCRINE DISEASE: Hypothyroidism-associated hyponatremia: mechanisms, implications and treatment.” European journal of endocrinology (2016). PMID: 27484454 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Clinical Presentation, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [55]
Piekiełko-Witkowska A, Elisei R, Leger J et al.. “EndoCompass project: research roadmap for thyroid endocrinology.” European journal of endocrinology (2025). PMID: 41104474 ↗
L5OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [56]
Peters C, Schoenmakers N. “MECHANISMS IN ENDOCRINOLOGY: The pathophysiology of transient congenital hypothyroidism.” European journal of endocrinology (2022). PMID: 35588090 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [57]
Biondi B. “Mechanisms in endocrinology: Heart failure and thyroid dysfunction.” European journal of endocrinology (2012). PMID: 22956554 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Complications and Long-term Sequelae - [58]
Tauber M, Hoybye C. “Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction.” The lancet. Diabetes & endocrinology (2021). PMID: 33647242 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [59]
De Leo S, Pearce EN. “Autoimmune thyroid disease during pregnancy.” The lancet. Diabetes & endocrinology (2017). PMID: 29246752 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [60]
Biondi B, Kahaly GJ, Robertson RP. “Thyroid Dysfunction and Diabetes Mellitus: Two Closely Associated Disorders.” Endocrine reviews (2019). PMID: 30649221 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [61]
Cheng SY, Leonard JL, Davis PJ. “Molecular aspects of thyroid hormone actions.” Endocrine reviews (2010). PMID: 20051527 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [62]
Han X, Han Z, Wang S et al.. “Causal risk and protective factors for rheumatoid arthritis: a comprehensive mendelian randomization systematic review and meta-analysis.” Frontiers in genetics (2026). PMID: 41928768 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [63]
Nauwynck E, Ryckx S, Klink D et al.. “Intrafamilial and age-dependent variability in Resistance to Thyroid Hormone Alpha: a case report.” Hormone research in paediatrics (2026). PMID: 42301959 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [64]
Park JY, Yoo SW, Kim SS et al.. “Hyperfunctioning distant metastases in high-grade differentiated thyroid carcinoma arising from HRAS-mutated follicular thyroid carcinoma: a case report and literature review.” Frontiers in endocrinology (2026). PMID: 41993975 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [65]
Sun J, Sun S, Sun Z et al.. “Case report: Thymoma-associated GAD65 autoimmunity: a unifying mechanism for multi-organ injury involving nervous, endocrine, and renal systems.” Frontiers in immunology (2026). PMID: 41909655 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [66]
Yüksel ŞD, Bağrıyanık EE, Bilicen E et al.. “Altered placental FoxP3 expression and exosome profile in maternal hypothyroidism.” Placenta (2026). PMID: 42341464 ↗
L5OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae - [67]
Westbye AB, Dahll LK, Bredahl MK et al.. “Thyroxine Treatment of Adult RTHα Patients: Safety, Efficacy, and Metabolomic Changes.” Thyroid : official journal of the American Thyroid Association (2026). PMID: 42273878 ↗
L4OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [68]
van Trotsenburg P, Stoupa A, Léger J et al.. “Congenital Hypothyroidism: A 2020-2021 Consensus Guidelines Update-An ENDO-European Reference Network Initiative Endorsed by the European Society for Pediatric Endocrinology and the European Society for Endocrinology.” Thyroid : official journal of the American Thyroid Association (2021). PMID: 33272083 ↗
L1GUIDELINECited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [69]
Garber JR, Cobin RH, Gharib H et al.. “Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association.” Thyroid : official journal of the American Thyroid Association (2012). PMID: 22954017 ↗
L1GUIDELINECited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [70]
Sankoda A, Suzuki H, Imaizumi M et al.. “Effects of Levothyroxine Treatment on Fertility and Pregnancy Outcomes in Subclinical Hypothyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Thyroid : official journal of the American Thyroid Association (2024). PMID: 38368537 ↗
L1SR_MA_RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [71]
Shakir MKM, Brooks DI, McAninch EA et al.. “Comparative Effectiveness of Levothyroxine, Desiccated Thyroid Extract, and Levothyroxine+Liothyronine in Hypothyroidism.” The Journal of clinical endocrinology and metabolism (2021). PMID: 34185829 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [72]
Garmendia Madariaga A, Santos Palacios S, Guillén-Grima F et al.. “The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis.” The Journal of clinical endocrinology and metabolism (2014). PMID: 24423323 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [73]
Beltrão FEL, Carvalhal G, Meneghini V et al.. “Treatment of Hypothyroidism That Contains Liothyronine is Associated With Reduced Risk of Dementia and Mortality.” The Journal of clinical endocrinology and metabolism (2026). PMID: 40579157 ↗
L3SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [74]
Pasqualetti G, Pagano G, Rengo G et al.. “Subclinical Hypothyroidism and Cognitive Impairment: Systematic Review and Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2015). PMID: 26305618 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History, Special Populations and Prevention - [75]
Roa Dueñas OH, Van der Burgh AC, Ittermann T et al.. “Thyroid Function and the Risk of Prediabetes and Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35137143 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors - [76]
Osinga JAJ, Nelson SM, Walsh JP et al.. “Defining Gestational Thyroid Dysfunction Through Modified Nonpregnancy Reference Intervals: An Individual Participant Meta-analysis.” The Journal of clinical endocrinology and metabolism (2024). PMID: 39083675 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History, Special Populations and Prevention - [77]
Casey BM, Thom EA, Peaceman AM et al.. “Treatment of Subclinical Hypothyroidism or Hypothyroxinemia in Pregnancy.” The New England journal of medicine (2017). PMID: 28249134 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [78]
Osinga JAJ, Liu Y, Männistö T et al.. “Risk Factors for Thyroid Dysfunction in Pregnancy: An Individual Participant Data Meta-Analysis.” Thyroid : official journal of the American Thyroid Association (2024). PMID: 38546971 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [79]
Mantovani A, Nascimbeni F, Lonardo A et al.. “Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.” Thyroid : official journal of the American Thyroid Association (2018). PMID: 30084737 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification, Complications and Long-term Sequelae - [80]
Sorensen JR, Winther KH, Bonnema SJ et al.. “Respiratory Manifestations of Hypothyroidism: A Systematic Review.” Thyroid : official journal of the American Thyroid Association (2016). PMID: 27673426 ↗
L5SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae - [81]
Gronich N, Deftereos SN, Lavi I et al.. “Hypothyroidism is a Risk Factor for New-Onset Diabetes: A Cohort Study.” Diabetes care (2015). PMID: 26070591 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [82]
Thvilum M, Lind SM, Ebbehoj E et al.. “Quality of life in patients with overt hypothyroidism: a systematic review.” European journal of endocrinology (2025). PMID: 40911397 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [83]
Hysaj O, Efthimiou O, Collet TH et al.. “Thyroid antibody status, thyroid function, and the risk of coronary heart disease and stroke: an individual participant data analysis from 14 cohorts.” European journal of endocrinology (2025). PMID: 41137464 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae - [84]
van Hulsteijn LT, Pasquali R, Casanueva F et al.. “Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis.” European journal of endocrinology (2020). PMID: 31652416 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors - [85]
Angelousi AG, Anagnostou VK, Stamatakos MK et al.. “Mechanisms in endocrinology: primary HT and risk for breast cancer: a systematic review and meta-analysis.” European journal of endocrinology (2011). PMID: 22023791 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors - [86]
Vitellius G, Poitou C, Clément K et al.. “Biallelic pathogenic variants in POMC can cause combined pituitary hormonal deficiency associated with severe obesity.” European journal of endocrinology (2025). PMID: 40513101 ↗
L4SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [87]
Alwan H, Villoz F, Feller M et al.. “Subclinical thyroid dysfunction and incident diabetes: a systematic review and an individual participant data analysis of prospective cohort studies.” European journal of endocrinology (2022). PMID: 36070417 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors - [88]
Osinga JAJ, Derakhshan A, Karachaliou M et al.. “Association of gestational thyroid function and thyroid autoimmunity with gestational diabetes: a systematic review and individual participant meta-analysis.” The lancet. Diabetes & endocrinology (2025). PMID: 40609565 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [89]
McKnight RF, Adida M, Budge K et al.. “Lithium toxicity profile: a systematic review and meta-analysis.” Lancet (London, England) (2012). PMID: 22265699 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [90]
de Fine Licht S, Winther JF, Gudmundsdottir T et al.. “Hospital contacts for endocrine disorders in Adult Life after Childhood Cancer in Scandinavia (ALiCCS): a population-based cohort study.” Lancet (London, England) (2014). PMID: 24556022 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [91]
Kitahara CM, Slettebø Daltveit D, Ekbom A et al.. “Maternal health, in-utero, and perinatal exposures and risk of thyroid cancer in offspring: a Nordic population-based nested case-control study.” The lancet. Diabetes & endocrinology (2020). PMID: 33347809 ↗
L3CASE_CONTROLCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [92]
Yang JK, Liu W, Shi J et al.. “An association between subclinical hypothyroidism and sight-threatening diabetic retinopathy in type 2 diabetic patients.” Diabetes care (2010). PMID: 20150298 ↗
L3OTHERCited in: Epidemiology, Etiology and Risk Factors - [93]
Mäkimattila S, Harjutsalo V, Forsblom C et al.. “Every Fifth Individual With Type 1 Diabetes Suffers From an Additional Autoimmune Disease: A Finnish Nationwide Study.” Diabetes care (2020). PMID: 32139386 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention - [94]
Rubio-Cabezas O, Minton JA, Caswell R et al.. “Clinical heterogeneity in patients with FOXP3 mutations presenting with permanent neonatal diabetes.” Diabetes care (2008). PMID: 18931102 ↗
L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [95]
Li Y, Teng D, Ba J et al.. “Efficacy and Safety of Long-Term Universal Salt Iodization on Thyroid Disorders: Epidemiological Evidence from 31 Provinces of Mainland China.” Thyroid : official journal of the American Thyroid Association (2020). PMID: 32075540 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors - [96]
Zimmermann MB, Boelaert K. “Iodine deficiency and thyroid disorders.” The lancet. Diabetes & endocrinology (2015). PMID: 25591468 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors - [97]
Biondi B, Cappola AR. “Subclinical hypothyroidism in older individuals.” The lancet. Diabetes & endocrinology (2021). PMID: 34953533 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [98]
Bagcchi S. “Hypothyroidism in India: more to be done.” The lancet. Diabetes & endocrinology (2014). PMID: 25282085 ↗
L5OTHERCited in: Epidemiology, Etiology and Risk Factors - [99]
Teng W, Shan Z, Teng X et al.. “Effect of iodine intake on thyroid diseases in China.” The New England journal of medicine (2006). PMID: 16807415 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors - [100]
Taylor PN, Medici MM, Hubalewska-Dydejczyk A et al.. “Hypothyroidism.” Lancet (London, England) (2024). PMID: 39368843 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [101]
Fleseriu M, Christ-Crain M, Langlois F et al.. “Hypopituitarism.” Lancet (London, England) (2024). PMID: 38735295 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [102]
Shine B, McKnight RF, Leaver L et al.. “Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data.” Lancet (London, England) (2015). PMID: 26003379 ↗
L3OTHERCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [103]
Hemminki K, Li X, Sundquist J et al.. “Familial association between type 1 diabetes and other autoimmune and related diseases.” Diabetologia (2009). PMID: 19543881 ↗
L3OTHERCited in: Epidemiology, Etiology and Risk Factors - [104]
Sun X, Kou C, Feng Y et al.. “The association between vitamin D and hypothyroidism: a systematic review and meta-analysis.” Nutrition & metabolism (2026). PMID: 42271402 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [105]
Ben Kridis W, Khanfir A. “Adjuvant Immune Checkpoint Inhibitors in Head and Neck Cancer: A Meta-Analysis of Phase III Trials.” Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology (2026). PMID: 42150812 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors - [106]
Wang X, Shang X, Li Y et al.. “Association between hypothyroidism, levothyroxine replacement and kidney function outcomes: a systematic review and meta-analysis.” Frontiers in endocrinology (2026). PMID: 42147108 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors - [107]
Sohn SY, Inoue K, Rhee CM et al.. “Risks of Iodine Excess.” Endocrine reviews (2024). PMID: 38870258 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Prognosis, Natural History, Special Populations and Prevention - [108]
Biondi B, Cooper DS. “The clinical significance of subclinical thyroid dysfunction.” Endocrine reviews (2007). PMID: 17991805 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [109]
Chang LS, Barroso-Sousa R, Tolaney SM et al.. “Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.” Endocrine reviews (2019). PMID: 30184160 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [110]
Reid SM, Middleton P, Cossich MC et al.. “Interventions for clinical and subclinical hypothyroidism pre-pregnancy and during pregnancy.” The Cochrane database of systematic reviews (2013). PMID: 23728666 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [111]
Villar HC, Saconato H, Valente O et al.. “Thyroid hormone replacement for subclinical hypothyroidism.” The Cochrane database of systematic reviews (2007). PMID: 17636722 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [112]
Ma C, Kuang A, Xie J et al.. “Radioiodine treatment for pediatric Graves' disease.” The Cochrane database of systematic reviews (2008). PMID: 18646146 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [113]
Abraham P, Avenell A, McGeoch SC et al.. “Antithyroid drug regimen for treating Graves' hyperthyroidism.” The Cochrane database of systematic reviews (2010). PMID: 20091544 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors - [114]
Reid SM, Middleton P, Cossich MC et al.. “Interventions for clinical and subclinical hypothyroidism in pregnancy.” The Cochrane database of systematic reviews (2010). PMID: 20614463 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [115]
Santos JAR, Christoforou A, Trieu K et al.. “Iodine fortification of foods and condiments, other than salt, for preventing iodine deficiency disorders.” The Cochrane database of systematic reviews (2019). PMID: 30746700 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [116]
Kim SY, Woo HA, Lee EH et al.. “Levothyroxine use and discontinuation in presumed congenital hypothyroidism: a 10-year nationwide cohort study.” Pediatric research (2026). PMID: 42304118 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [117]
Feng X, Lyu X, Gao Y et al.. “Analysis of risk factors for hypothyroidism in initially euthyroid patients with positive thyroid autoantibodies: a multicenter retrospective cohort study.” Frontiers in endocrinology (2026). PMID: 42232752 ↗
L3COHORTCited in: Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification - [118]
Saleh M, Almashaiekh TM, Thabaineh RW et al.. “Epidemiology and demographic trends of sarcoidosis in southern West Bank, Palestine: a retrospective study (2019-2024).” BMC public health (2026). PMID: 42174489 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [119]
Léger J, Olivieri A, Donaldson M et al.. “European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism.” The Journal of clinical endocrinology and metabolism (2014). PMID: 24446653 ↗
L1GUIDELINECited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [120]
Ramiandrasoa C, Castinetti F, Raingeard I et al.. “Delayed diagnosis of Sheehan's syndrome in a developed country: a retrospective cohort study.” European journal of endocrinology (2013). PMID: 23864341 ↗
L3COHORTCited in: Clinical Presentation, Acute Management and Endocrine Emergencies - [121]
Stagnaro-Green A. “Approach to the patient with postpartum thyroiditis.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22312089 ↗
L5CASE_REPORTCited in: Clinical Presentation - [122]
Yamauchi I, Sakane Y, Fukuda Y et al.. “Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.” Thyroid : official journal of the American Thyroid Association (2017). PMID: 28537531 ↗
L4CASE_REPORTCited in: Clinical Presentation - [123]
Pine-Twaddell E, Romero CJ, Radovick S. “Vertical transmission of hypopituitarism: critical importance of appropriate interpretation of thyroid function tests and levothyroxine therapy during pregnancy.” Thyroid : official journal of the American Thyroid Association (2013). PMID: 23397938 ↗
L4CASE_REPORTCited in: Clinical Presentation - [124]
Law JH, Dean DS, Scheithauer B et al.. “Symptomatic amyloid goiters: report of five cases.” Thyroid : official journal of the American Thyroid Association (2013). PMID: 23544771 ↗
L4CASE_REPORTCited in: Clinical Presentation - [125]
Hoang TD, Mai VQ, Clyde PW et al.. “Simultaneous occurrence of subacute thyroiditis and Graves' disease.” Thyroid : official journal of the American Thyroid Association (2011). PMID: 22136271 ↗
L4CASE_REPORTCited in: Clinical Presentation - [126]
Mallipedhi A, Vali H, Okosieme O. “Myxedema coma in a patient with subclinical hypothyroidism.” Thyroid : official journal of the American Thyroid Association (2010). PMID: 21058937 ↗
L4CASE_REPORTCited in: Clinical Presentation, Acute Management and Endocrine Emergencies - [127]
Brugts MP, Luermans JG, Lentjes EG et al.. “Heterophilic antibodies may be a cause of falsely low total IGF1 levels.” European journal of endocrinology (2009). PMID: 19608715 ↗
L4CASE_REPORTCited in: Clinical Presentation - [128]
Nakhleh A, Robenshtok E, Adler L et al.. “Clinical Characteristics and Outcomes of Graves' Disease in Individuals with Prior Hypothyroidism.” The Journal of clinical endocrinology and metabolism (2026). PMID: 40709412 ↗
L3OTHERCited in: Clinical Presentation - [129]
Hennessey JV. “Clinical review: Riedel's thyroiditis: a clinical review.” The Journal of clinical endocrinology and metabolism (2011). PMID: 21832114 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [130]
Park S, Jeon MJ, Song E et al.. “Clinical Features of Early and Late Postoperative Hypothyroidism After Lobectomy.” The Journal of clinical endocrinology and metabolism (2017). PMID: 28324106 ↗
L2OTHERCited in: Clinical Presentation - [131]
Ludar H, Levy-Shraga Y, Admoni O et al.. “Clinical and Molecular Characteristics and Long-term Follow-up of Children With Pseudohypoparathyroidism Type IA.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37669316 ↗
L4OTHERCited in: Clinical Presentation - [132]
Uehara E, Abe K, Tanase-Nakao K et al.. “Molecular and Clinical Features of Congenital Hypothyroidism Due to Multiple DUOX2 Variants.” Thyroid : official journal of the American Thyroid Association (2024). PMID: 38757580 ↗
L4OTHERCited in: Clinical Presentation - [133]
Wilding JPH. “Endocrine testing in obesity.” European journal of endocrinology (2020). PMID: 32061161 ↗
L5OTHERCited in: Clinical Presentation, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [134]
Tagliafico A, Resmini E, Nizzo R et al.. “The pathology of the ulnar nerve in acromegaly.” European journal of endocrinology (2008). PMID: 18632873 ↗
L2OTHERCited in: Clinical Presentation, Acute Management and Endocrine Emergencies - [135]
Pandit R, Channaiah CY, Lila AR et al.. “Long-term outcomes of pituitary radiotherapy and their predictive factors in childhood and adolescent-onset Cushing disease.” European journal of endocrinology (2025). PMID: 40705853 ↗
L4OTHERCited in: Clinical Presentation - [136]
Al-Soleiti M, Park JH, Kummerlowe MN et al.. “Clinical Characteristics and Treatment of Benzodiazepine Withdrawal Delirium in Adults: An Illustrative Case and Systematic Review of Published Cases.” Journal of the Academy of Consultation-Liaison Psychiatry (2026). PMID: 42270080 ↗
L5SR_OBSCited in: Clinical Presentation, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [137]
Donno F, Bianco F, Schininà R et al.. “Chung-Jansen Syndrome in a Young Woman with a PHIP Variant: Severe Obesity, Intellectual Disability, and Endocrine Abnormalities.” Journal of clinical medicine (2026). PMID: 42355777 ↗
L4CASE_REPORTCited in: Clinical Presentation, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [138]
Cui M, Yu Z, Du Q et al.. “Decompensated liver cirrhosis as a rare consequence of long-term untreated panhypopituitarism after craniopharyngioma resection: a case report.” Frontiers in endocrinology (2026). PMID: 42232758 ↗
L4CASE_REPORTCited in: Clinical Presentation - [139]
Maghdi SA, Moshi JM, Hakami AA et al.. “Recurrent primary hyperparathyroidism with ipsilateral multifocal papillary thyroid carcinoma of classical, warthin-like, and follicular variants harboring distinct BRAF and NRAS mutations: a rare case report.” World journal of surgical oncology (2026). PMID: 42106728 ↗
L4CASE_REPORTCited in: Clinical Presentation - [140]
Shi L, Wang J, Xie X et al.. “Case report and literature review: isolated ACTH deficiency induced by combined nivolumab and trastuzumab therapy in gastric adenocarcinoma.” Frontiers in endocrinology (2026). PMID: 42087875 ↗
L5CASE_REPORTCited in: Clinical Presentation, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [141]
Prasad S, Sharma S, Agrawal S et al.. “Case Report: Beyond metabolism: subclinical hypothyroidism associated with chronic alveolar hypoventilation.” Frontiers in medicine (2026). PMID: 41907252 ↗
L4CASE_REPORTCited in: Clinical Presentation - [142]
De Groot L, Abalovich M, Alexander EK et al.. “Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22869843 ↗
L1GUIDELINECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [143]
Jonklaas J, Bianco AC, Bauer AJ et al.. “Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.” Thyroid : official journal of the American Thyroid Association (2014). PMID: 25266247 ↗
L1GUIDELINECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [144]
Floriani C, Feller M, Aubert CE et al.. “Thyroid Dysfunction and Anemia: A Prospective Cohort Study and a Systematic Review.” Thyroid : official journal of the American Thyroid Association (2018). PMID: 29631476 ↗
L2SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [145]
Derakhshan A, Peeters RP, Taylor PN et al.. “Association of maternal thyroid function with birthweight: a systematic review and individual-participant data meta-analysis.” The lancet. Diabetes & endocrinology (2020). PMID: 32445737 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [146]
Lee SY, Pearce EN. “Testing, Monitoring, and Treatment of Thyroid Dysfunction in Pregnancy.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33349844 ↗
L5CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [147]
Roa Dueñas OH, Hofman A, Luik AI et al.. “The Cross-sectional and Longitudinal Association Between Thyroid Function and Depression: A Population-Based Study.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37855318 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [148]
Perheentupa J. “Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.” The Journal of clinical endocrinology and metabolism (2006). PMID: 16684821 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [149]
Alexander EK, Pearce EN, Brent GA et al.. “2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum.” Thyroid : official journal of the American Thyroid Association (2017). PMID: 28056690 ↗
L1OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [150]
Jasim S, Papaleontiou M. “Considerations in the Diagnosis and Management of Thyroid Dysfunction in Older Adults.” Thyroid : official journal of the American Thyroid Association (2025). PMID: 40376729 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [151]
Jansen HI, Dirks NF, Hillebrand JJ et al.. “Age-Specific Reference Intervals for Thyroid-Stimulating Hormones and Free Thyroxine to Optimize Diagnosis of Thyroid Disease.” Thyroid : official journal of the American Thyroid Association (2024). PMID: 39283820 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [152]
Peters C, van Trotsenburg ASP, Schoenmakers N. “DIAGNOSIS OF ENDOCRINE DISEASE: Congenital hypothyroidism: update and perspectives.” European journal of endocrinology (2018). PMID: 30324792 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [153]
Hamblin R, Fountas A, Lithgow K et al.. “Natural history of non-functioning pituitary microadenomas: results from the UK non-functioning pituitary adenoma consortium.” European journal of endocrinology (2023). PMID: 37345849 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [154]
Iglesias P, Díez JJ. “Thyroid dysfunction and kidney disease.” European journal of endocrinology (2008). PMID: 19095779 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [155]
Boelaert K, Visser WE, Taylor PN et al.. “ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of hyperthyroidism and hypothyroidism.” European journal of endocrinology (2020). PMID: 32438340 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [156]
Velasco I, Taylor P. “Identifying and treating subclinical thyroid dysfunction in pregnancy: emerging controversies.” European journal of endocrinology (2017). PMID: 29070512 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae - [157]
Welsh KJ, Soldin SJ. “DIAGNOSIS OF ENDOCRINE DISEASE: How reliable are free thyroid and total T3 hormone assays?” European journal of endocrinology (2016). PMID: 27737898 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [158]
Cooper DS, Laurberg P. “Hyperthyroidism in pregnancy.” The lancet. Diabetes & endocrinology (2013). PMID: 24622372 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [159]
Johnson MB, Hattersley AT, Flanagan SE. “Monogenic autoimmune diseases of the endocrine system.” The lancet. Diabetes & endocrinology (2016). PMID: 27474216 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [160]
Moreno JC, Klootwijk W, van Toor H et al.. “Mutations in the iodotyrosine deiodinase gene and hypothyroidism.” The New England journal of medicine (2008). PMID: 18434651 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [161]
Kemkem Y, Nasteska D, de Bray A et al.. “Maternal hypothyroidism in mice influences glucose metabolism in adult offspring.” Diabetologia (2020). PMID: 32472193 ↗
L5OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History, Special Populations and Prevention - [162]
Ma C, Xie J, Wang H et al.. “Radioiodine therapy versus antithyroid medications for Graves' disease.” The Cochrane database of systematic reviews (2016). PMID: 26891370 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [163]
Spencer L, Bubner T, Bain E et al.. “Screening and subsequent management for thyroid dysfunction pre-pregnancy and during pregnancy for improving maternal and infant health.” The Cochrane database of systematic reviews (2015). PMID: 26387772 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [164]
Ng SM, Anand D, Weindling AM. “High versus low dose of initial thyroid hormone replacement for congenital hypothyroidism.” The Cochrane database of systematic reviews (2009). PMID: 19160309 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [165]
Peluso A, Aljawfi O, Anderson KM et al.. “Health care utilization before and after COVID-19 diagnosis: a multidisease matched-cohort study by sociodemographic factors.” BMC health services research (2026). PMID: 42343378 ↗
L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies - [166]
Shin W, Weatherbee M, Rehan Z et al.. “Malnutrition in Older Adults With Chronic Wounds: A Prospective Cohort Study.” Advances in skin & wound care (2026). PMID: 42340170 ↗
L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History, Special Populations and Prevention - [167]
Nair A, Doughty V, Vazquez-Garcia L et al.. “Spectrum of potentially lethal cardiac conditions presenting with fetal sinus bradycardia: a report on 34 cases.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2026). PMID: 42333052 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [168]
Lum CL, Tay WL, Chiang BS et al.. “Assay-dependent variability in free thyroxine (FT4): differential interference related to immunoassay design in a patient with subclinical hypothyroidism.” Journal of clinical pathology (2026). PMID: 42331602 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [169]
Guerra-Ruiz AR, Millan MM, Real Bolt AD et al.. “Diagnosis of familial dysbetalipoproteinemia due to APOE p.(Arg154Ser): The role of ultracentrifugation and lipid ratios.” Journal of clinical lipidology (2026). PMID: 42315422 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [170]
Chang CY, Chien YJ, Lin PC et al.. “Nonthyroidal Illness Syndrome and Hypothyroidism in Ischemic Heart Disease Population: A Systematic Review and Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32459357 ↗
L2SR_OBSCited in: Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae - [171]
Bahl S, Taylor PN, Premawardhana LD et al.. “Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40795305 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification - [172]
Kotwal A, Cortes T, Genere N et al.. “Treatment of Thyroid Dysfunction and Serum Lipids: A Systematic Review and Meta-analysis.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32954428 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification - [173]
Moon S, Kim MJ, Yu JM et al.. “Subclinical Hypothyroidism and the Risk of Cardiovascular Disease and All-Cause Mortality: A Meta-Analysis of Prospective Cohort Studies.” Thyroid : official journal of the American Thyroid Association (2018). PMID: 29978767 ↗
L2SR_OBSCited in: Severity, Staging and Risk Stratification, Complications and Long-term Sequelae - [174]
Bano A, Chaker L, Muka T et al.. “Thyroid Function and the Risk of Fibrosis of the Liver, Heart, and Lung in Humans: A Systematic Review and Meta-Analysis.” Thyroid : official journal of the American Thyroid Association (2020). PMID: 31910097 ↗
L2SR_OBSCited in: Severity, Staging and Risk Stratification - [175]
Pergialiotis V, Konstantopoulos P, Prodromidou A et al.. “MANAGEMENT OF ENDOCRINE DISEASE: The impact of subclinical hypothyroidism on anthropometric characteristics, lipid, glucose and hormonal profile of PCOS patients: a systematic review and meta-analysis.” European journal of endocrinology (2016). PMID: 28007842 ↗
L2SR_OBSCited in: Severity, Staging and Risk Stratification - [176]
Bogazzi F, Bartalena L, Martino E. “Approach to the patient with amiodarone-induced thyrotoxicosis.” The Journal of clinical endocrinology and metabolism (2010). PMID: 20525904 ↗
L5CASE_REPORTCited in: Severity, Staging and Risk Stratification - [177]
Barzon L, Masi G, Boschin IM et al.. “Characterization of a novel complex BRAF mutation in a follicular variant papillary thyroid carcinoma.” European journal of endocrinology (2008). PMID: 18426810 ↗
L4CASE_REPORTCited in: Severity, Staging and Risk Stratification - [178]
de Lange TE, Simsek S, Kramer MH et al.. “A case of cocaine-induced panhypopituitarism with human neutrophil elastase-specific anti-neutrophil cytoplasmic antibodies.” European journal of endocrinology (2008). PMID: 19114541 ↗
L4CASE_REPORTCited in: Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies - [179]
Léger J. “Congenital hypothyroidism: a clinical update of long-term outcome in young adults.” European journal of endocrinology (2014). PMID: 25225479 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging and Risk Stratification - [180]
Pani F, Massidda M, Pusceddu V et al.. “Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link?” European journal of endocrinology (2017). PMID: 28468766 ↗
L2OTHERCited in: Severity, Staging and Risk Stratification - [181]
Fliers E, Bianco AC, Langouche L et al.. “Thyroid function in critically ill patients.” The lancet. Diabetes & endocrinology (2015). PMID: 26071885 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [182]
Zhang W, Piao F, Fu W et al.. “Thyroid dysfunction and risk of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy: a multicenter cohort study.” Frontiers in endocrinology (2026). PMID: 42077455 ↗
L3COHORTCited in: Severity, Staging and Risk Stratification - [183]
Kornerup LS, Kraglund F, Vilstrup H et al.. “Risk and prognosis of HCC in patients with thyroid disease: A nationwide cohort study.” Hepatology communications (2025). PMID: 41961637 ↗
L2COHORTCited in: Severity, Staging and Risk Stratification - [184]
Yin P, Wu J, Zhao H et al.. “Early Transient Hypothyroidism Is Associated With Long-Term Outcomes of 131I Treatment in Graves' Disease: A Retrospective Cohort Study.” Clinical endocrinology (2026). PMID: 42098592 ↗
L3COHORTCited in: Severity, Staging and Risk Stratification - [185]
Mebis L, Paletta D, Debaveye Y et al.. “Expression of thyroid hormone transporters during critical illness.” European journal of endocrinology (2009). PMID: 19439506 ↗
L2RCTCited in: Acute Management and Endocrine Emergencies - [186]
de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ et al.. “A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma.” The Journal of clinical endocrinology and metabolism (2007). PMID: 17579194 ↗
L2TRIAL_NONRANDOMCited in: Acute Management and Endocrine Emergencies - [187]
Cappelli C, Rotondi M, Pirola I et al.. “TSH-lowering effect of metformin in type 2 diabetic patients: differences between euthyroid, untreated hypothyroid, and euthyroid on L-T4 therapy patients.” Diabetes care (2009). PMID: 19502536 ↗
L2TRIAL_NONRANDOMCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [188]
Turunen S, Vääräsmäki M, Männistö T et al.. “Pregnancy and Perinatal Outcome Among Hypothyroid Mothers: A Population-Based Cohort Study.” Thyroid : official journal of the American Thyroid Association (2018). PMID: 30417761 ↗
L2COHORTCited in: Acute Management and Endocrine Emergencies - [189]
Xiong X, Wong CKH, Au ICH et al.. “Safety of Inactivated and mRNA COVID-19 Vaccination Among Patients Treated for Hypothyroidism: A Population-Based Cohort Study.” Thyroid : official journal of the American Thyroid Association (2022). PMID: 35216517 ↗
L2COHORTCited in: Acute Management and Endocrine Emergencies - [190]
Akturk HK, Alkanani A, Zhao Z et al.. “PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity.” The Journal of clinical endocrinology and metabolism (2018). PMID: 30124874 ↗
L4CASE_REPORTCited in: Acute Management and Endocrine Emergencies - [191]
Tng EL, Aung AT, Chong N. “Myxedema Coma Precipitated by Iohexol: Case Report and Brief Literature Review on the Wolff-Chaikoff Effect.” Thyroid : official journal of the American Thyroid Association (2022). PMID: 35180827 ↗
L4CASE_REPORTCited in: Acute Management and Endocrine Emergencies - [192]
Phillips BD, Gopalakrishnan G, Gohh R et al.. “Lithium toxicity precipitated by profound hypothyroidism.” Thyroid : official journal of the American Thyroid Association (2008). PMID: 18578616 ↗
L4CASE_REPORTCited in: Acute Management and Endocrine Emergencies - [193]
Dutta D, Mukhopadhyay S, Maisnam I et al.. “Neuroendocrine carcinoma of the thyroid causing adrenocorticotrophic hormone-dependent Cushing's syndrome.” Thyroid : official journal of the American Thyroid Association (2013). PMID: 23140512 ↗
L4CASE_REPORTCited in: Acute Management and Endocrine Emergencies - [194]
Ladenson PW. “Precision Medicine Comes to Thyroidology.” The Journal of clinical endocrinology and metabolism (2016). PMID: 26908108 ↗
L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies - [195]
Lado-Abeal J, Munir I, Al-Zubaidi K et al.. “Heart ventricular function in hospitalized patients with severe hypothyroidism and myxedema coma.” The Journal of clinical endocrinology and metabolism (2026). PMID: 41612686 ↗
L3OTHERCited in: Acute Management and Endocrine Emergencies - [196]
Mehrotra-Varma S, Hadidchi R, Henry SS et al.. “Elevated Risk of New-Onset Thyroid Disease Associated With SARS-CoV-2 Infection: A 4.5-Year Observational Study.” The Journal of clinical endocrinology and metabolism (2026). PMID: 41433356 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies - [197]
Penna GC, Bianco AC, Ettleson MD. “A Cross-Sectional Analysis of Cardiovascular and Bone Health Care Utilization During Treatment With Thyroid Hormone.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37878964 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies - [198]
Weber J, Tanawattanacharoen VK, Seagroves A et al.. “Low Adrenomedullary Function Predicts Acute Illness in Infants With Classical Congenital Adrenal Hyperplasia.” The Journal of clinical endocrinology and metabolism (2022). PMID: 34397083 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies - [199]
Silva JE, Bianco SD. “Thyroid-adrenergic interactions: physiological and clinical implications.” Thyroid : official journal of the American Thyroid Association (2008). PMID: 18279016 ↗
L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies - [200]
Lania A, Sandri MT, Cellini M et al.. “Thyrotoxicosis in patients with COVID-19: the THYRCOV study.” European journal of endocrinology (2020). PMID: 32698147 ↗
L3OTHERCited in: Acute Management and Endocrine Emergencies - [201]
Duntas LH, Biondi B. “Short-term hypothyroidism after Levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences.” European journal of endocrinology (2007). PMID: 17218721 ↗
L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies - [202]
Takada T, Tambas M, Clementel E et al.. “Prognostic models for radiation-induced complications after radiotherapy in head and neck cancer patients.” The Cochrane database of systematic reviews (2025). PMID: 40927975 ↗
L2SR_OBSCited in: Acute Management and Endocrine Emergencies - [203]
Deng C, Inoue K, Saechao C et al.. “Maternal Thyroid Diseases, Medication Use and Childhood Cancer Risks in Offspring: A Population-Based Cohort Study in Denmark.” International journal of cancer (2026). PMID: 42260983 ↗
L3COHORTCited in: Acute Management and Endocrine Emergencies - [204]
Gao X, Chang W, Sun K et al.. “Lithium carbonate bridging and outcomes of radioiodine therapy in severe Graves' disease: a retrospective cohort study.” Frontiers in endocrinology (2026). PMID: 42181214 ↗
L3COHORTCited in: Acute Management and Endocrine Emergencies - [205]
Hommos L, Gohil H, Rob M et al.. “Long-Term Thyroid Complications Post-COVID-19: A Systematic Review.” Microorganisms (2026). PMID: 41900303 ↗
L1SR_OBSCited in: Acute Management and Endocrine Emergencies - [206]
Taborda MH, Pedro MKF, Corrêa de Almeida Teixeira B. “Case 349.” Radiology (2026). PMID: 42048593 ↗
L4CASE_REPORTCited in: Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [207]
Diz Ferre JL, Zhou G, Cabulong A et al.. “Outcomes of Cardiovascular Surgery in Patients With Multiple Sclerosis.” JAMA surgery (2026). PMID: 42268624 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies - [208]
Guan B, Lin L, Chen Z et al.. “Development of a machine learning-based prediction model for hypothyroidism-associated delirium in elderly hypothyroid patients in the intensive care unit.” BMC geriatrics (2026). PMID: 42260388 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies - [209]
Jonklaas J, Bianco AC, Cappola AR et al.. “Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document.” Thyroid : official journal of the American Thyroid Association (2021). PMID: 33276704 ↗
L1GUIDELINECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [210]
Willems JIA, van Twist DJL, Helmich F et al.. “Fasting vs Nonfasting, Dose-adjusted Levothyroxine Ingestion in Hypothyroidism: A Randomized Clinical Trial.” The Journal of clinical endocrinology and metabolism (2026). PMID: 41431302 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [211]
Kim MK, Kwon HS, Baek KH et al.. “Effects of thyroid hormone on A1C and glycated albumin levels in nondiabetic subjects with overt hypothyroidism.” Diabetes care (2010). PMID: 20823345 ↗
L3RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [212]
de Lima Beltrão FE, Carvalhal G, de Almeida Beltrão DC et al.. “Treatment Preferences in Patients With Hypothyroidism.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39290156 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [213]
Stott DJ, Rodondi N, Kearney PM et al.. “Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism.” The New England journal of medicine (2017). PMID: 28402245 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [214]
Lazarus JH, Bestwick JP, Channon S et al.. “Antenatal thyroid screening and childhood cognitive function.” The New England journal of medicine (2012). PMID: 22316443 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [215]
Maraka S, Ospina NM, O'Keeffe DT et al.. “Subclinical Hypothyroidism in Pregnancy: A Systematic Review and Meta-Analysis.” Thyroid : official journal of the American Thyroid Association (2016). PMID: 26837268 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [216]
Cohen EEW, Soulières D, Le Tourneau C et al.. “Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.” Lancet (London, England) (2018). PMID: 30509740 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [217]
Groeneweg S, Peeters RP, Moran C et al.. “Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial.” The lancet. Diabetes & endocrinology (2019). PMID: 31377265 ↗
L2TRIAL_NONRANDOMCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae - [218]
Gillmore JD, Gane E, Täubel J et al.. “Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy.” The New England journal of medicine (2025). PMID: 41002250 ↗
L4TRIAL_NONRANDOMCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [219]
Toloza FJK, Derakhshan A, Männistö T et al.. “Association between maternal thyroid function and risk of gestational hypertension and pre-eclampsia: a systematic review and individual-participant data meta-analysis.” The lancet. Diabetes & endocrinology (2022). PMID: 35255260 ↗
L2SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [220]
Korevaar TI, Muetzel R, Medici M et al.. “Association of maternal thyroid function during early pregnancy with offspring IQ and brain morphology in childhood: a population-based prospective cohort study.” The lancet. Diabetes & endocrinology (2015). PMID: 26497402 ↗
L2COHORTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [221]
Persani L. “Clinical review: Central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22851492 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [222]
Man R, Dhillon-Smith R, Korevaar TIM. “Levothyroxine supplementation trials in preconception and pregnant women.” European journal of endocrinology (2025). PMID: 39943743 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [223]
Jonklaas J. “Optimal Thyroid Hormone Replacement.” Endocrine reviews (2022). PMID: 34543420 ↗
L5OTHERCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [224]
Biondi B, Wartofsky L. “Treatment with thyroid hormone.” Endocrine reviews (2014). PMID: 24433025 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [225]
Virili C, Antonelli A, Santaguida MG et al.. “Gastrointestinal Malabsorption of Thyroxine.” Endocrine reviews (2019). PMID: 30476027 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [226]
Bonnema SJ, Hegedüs L. “Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome.” Endocrine reviews (2012). PMID: 22961916 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [227]
Ke LQ, Hu Y, Yang K et al.. “Chinese herbal medicines for hypothyroidism.” The Cochrane database of systematic reviews (2015). PMID: 25914906 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [228]
Das A, Shah PS. “Octreotide for the treatment of chylothorax in neonates.” The Cochrane database of systematic reviews (2010). PMID: 20824848 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [229]
Huo Y, Xie J, Chen S et al.. “Recombinant human thyrotropin (rhTSH)-aided radioiodine treatment for non-toxic multinodular goitre.” The Cochrane database of systematic reviews (2021). PMID: 34961921 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [230]
Akhtar MA, Agrawal R, Brown J et al.. “Thyroxine replacement for subfertile women with euthyroid autoimmune thyroid disease or subclinical hypothyroidism.” The Cochrane database of systematic reviews (2019). PMID: 31236916 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [231]
Atias D, Allon R, Ben-Basat N et al.. “Gestational Hypothyroidism and Pregnancy Outcomes Following Hemithyroidectomy: A Nationwide Matched Cohort Study.” The Journal of clinical endocrinology and metabolism (2026). PMID: 42274355 ↗
L2COHORTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [232]
Manna S, Mukherjee R, Kandpal V et al.. “Prevalence of hypothyroidism among pregnant women and associated feto-maternal outcomes in India: Systematic review and meta-analysis.” The Indian journal of medical research (2026). PMID: 42295724 ↗
L2SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [233]
Dai W, Li Q, Wang M et al.. “Associations between systemic immune-inflammation index and immune-related hypothyroidism in non-small cell lung cancer patients receiving immune checkpoint inhibitors: a retrospective study.” Frontiers in oncology (2026). PMID: 42311250 ↗
L3COHORTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [234]
Hedberg F, Lindh JD, Mannheimer B et al.. “Psychiatric morbidity following liothyronine exposure in autoimmune hypothyroidism: a Swedish nationwide cohort study.” Journal of the Endocrine Society (2026). PMID: 42255516 ↗
L2COHORTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [235]
. “Ablative Technologies for Thyroid Nodules: A Health Technology Assessment.” Ontario health technology assessment series (2026). PMID: 42311839 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [236]
Wu Y, Li H, Peng Y et al.. “Sustained complete response to TMEp-CI-M platform in refractory small-cell lung cancer with brainstem metastasis: a case report with over 20 months of disease-free survival.” Frontiers in immunology (2026). PMID: 42305556 ↗
L4CASE_REPORTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [237]
Bishnoi A, Shekhawat V, Nachankar A. “Prevalence of Various Endocrinopathies Resulting from Use of Immune Checkpoint Inhibitors - A Prospective Study from a Tertiary Care Centre in India.” Indian journal of endocrinology and metabolism (2026). PMID: 42238555 ↗
L2COHORTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [238]
David O, Barash G, Agur R et al.. “Multiple Endocrine Deficiencies are Common in Hypoparathyroidism-Retardation-Dysmorphism Syndrome.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33150438 ↗
L4TRIAL_NONRANDOMCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [239]
Lauffer P, Zwaveling-Soonawala N, Li S et al.. “Meta-Analysis of DNA Methylation Datasets Shows Aberrant DNA Methylation of Thyroid Development or Function Genes in Down Syndrome.” Thyroid : official journal of the American Thyroid Association (2022). PMID: 36326208 ↗
L2SR_OBSCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [240]
Wu Z, Jiang Y, Zhou D et al.. “Sex-specific Association of Subclinical Hypothyroidism With Incident Metabolic Syndrome: A Population-based Cohort Study.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35213715 ↗
L2COHORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [241]
Bosch E, Hebebrand M, Popp B et al.. “BDV Syndrome: An Emerging Syndrome With Profound Obesity and Neurodevelopmental Delay Resembling Prader-Willi Syndrome.” The Journal of clinical endocrinology and metabolism (2021). PMID: 34383079 ↗
L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [242]
Villafuerte B, Carrasco-López C, Herranz A et al.. “A Novel Missense Variant in the NKX2-1 Homeodomain Prevents Transcriptional Rescue by TAZ.” Thyroid : official journal of the American Thyroid Association (2024). PMID: 38757609 ↗
L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [243]
Kandasamy N, Fugazzola L, Evans M et al.. “Life-threatening metabolic alkalosis in Pendred syndrome.” European journal of endocrinology (2011). PMID: 21551164 ↗
L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [244]
Dimitri P, Warner JT, Minton JA et al.. “Novel GLIS3 mutations demonstrate an extended multisystem phenotype.” European journal of endocrinology (2010). PMID: 21139041 ↗
L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [245]
Höybye C, Tauber M. “Approach to the Patient With Prader-Willi Syndrome.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35150573 ↗
L5OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae - [246]
Meling Stokland AE, Ueland G, Lima K et al.. “Autoimmune Thyroid Disorders in Autoimmune Addison Disease.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35226748 ↗
L2OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [247]
Chng CL, Goh GBB, Yen PM. “Metabolic and Functional Cross Talk Between the Thyroid and Liver.” Thyroid : official journal of the American Thyroid Association (2025). PMID: 40420529 ↗
L5REVIEW_NARRATIVECited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [248]
Bianco AC. “We All Know We Need Them, We Hope They Are Coming, But When?” Thyroid : official journal of the American Thyroid Association (2020). PMID: 32228170 ↗
L5OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [249]
Li GH, Tang CM, Cheung CL. “COVID-19 and Thyroid Function: A Bi-Directional Two-Sample Mendelian Randomization Study.” Thyroid : official journal of the American Thyroid Association (2022). PMID: 35734897 ↗
L2OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [250]
Franchini M, Lippi G, Manzato F et al.. “Hemostatic abnormalities in endocrine and metabolic disorders.” European journal of endocrinology (2009). PMID: 19934268 ↗
L5REVIEW_NARRATIVECited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [251]
Pepe G, Corica D, De Sanctis L et al.. “Prospective evaluation of autoimmune and non-autoimmune subclinical hypothyroidism in Down syndrome children.” European journal of endocrinology (2020). PMID: 31999620 ↗
L2OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [252]
Cranston T, Boon H, Olesen MK et al.. “Spectrum of germline AIRE mutations causing APS-1 and familial hypoparathyroidism.” European journal of endocrinology (2022). PMID: 35521792 ↗
L4OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [253]
Deng HR, Lin SY, Zhang FY et al.. “Multiple endocrine dysfunctions in twins with Wilson's disease: two case reports Deng et al. endocrine dysfunctions in Wilson's disease.” BMC women's health (2026). PMID: 41975374 ↗
L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [254]
Maslennikov R, Agarkova V, Poluektova E et al.. “Treatment of Small Intestinal Bacterial Overgrowth (SIBO) in Gastrointestinal, Hepatic, Endocrine, Neurological, and Postoperative Diseases: A Comprehensive Narrative Review.” Medical sciences (Basel, Switzerland) (2026). PMID: 42346839 ↗
L5REVIEW_NARRATIVECited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [255]
Krishnan M, Chawla KK, Gudimalla A et al.. “Genetic and Metabolic Basis of Increased Diabetes Mellitus Risk in Down Syndrome: A Narrative Review.” Canadian journal of diabetes (2026). PMID: 42270076 ↗
L5REVIEW_NARRATIVECited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [256]
Tsai TY, Tu YK, Munir KM et al.. “Association of Hypothyroidism and Mortality in the Elderly Population: A Systematic Review and Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2020). PMID: 31829418 ↗
L1SR_OBSCited in: Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [257]
Peng CC, Huang HK, Wu BB et al.. “Association of Thyroid Hormone Therapy with Mortality in Subclinical Hypothyroidism: A Systematic Review and Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33107557 ↗
L1SR_OBSCited in: Complications and Long-term Sequelae - [258]
Riis KR, Larsen CB, Bonnema SJ. “Potential Risks and Benefits of Desiccated Thyroid Extract for the Treatment of Hypothyroidism: A Systematic Review.” Thyroid : official journal of the American Thyroid Association (2024). PMID: 38526391 ↗
L1SR_OBSCited in: Complications and Long-term Sequelae - [259]
Danner E, Jääskeläinen J, Niuro L et al.. “Comorbidity in Congenital Hypothyroidism-A Nationwide, Population-based Cohort Study.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37279943 ↗
L2COHORTCited in: Complications and Long-term Sequelae - [260]
Haentjens P, Van Meerhaeghe A, Poppe K et al.. “Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies.” European journal of endocrinology (2008). PMID: 18511471 ↗
L1SR_OBSCited in: Complications and Long-term Sequelae - [261]
Ran X, Wang N, Zhao T et al.. “Hypothyroidism and Risks of All-Cause and Cardiovascular Mortality: A Retrospective Cohort Study of 70,276 Chinese Adults.” Thyroid : official journal of the American Thyroid Association (2025). PMID: 41213612 ↗
L3COHORTCited in: Complications and Long-term Sequelae - [262]
Cheng Y, Hu H, Li W et al.. “Chronic Kidney Disease and Thyroid Hormones.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39657910 ↗
L3OTHERCited in: Complications and Long-term Sequelae - [263]
Vargas F, Moreno JM, Rodríguez-Gómez I et al.. “Vascular and renal function in experimental thyroid disorders.” European journal of endocrinology (2006). PMID: 16452532 ↗
L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae - [264]
Sbardella E, Pozza C, Isidori AM et al.. “ENDOCRINOLOGY AND ADOLESCENCE: Dealing with transition in young patients with pituitary disorders.” European journal of endocrinology (2019). PMID: 31370006 ↗
L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae - [265]
Lillevang-Johansen M, Abrahamsen B, Jørgensen HL et al.. “Duration of over- and under-treatment of hypothyroidism is associated with increased cardiovascular risk.” European journal of endocrinology (2019). PMID: 31035256 ↗
L3OTHERCited in: Complications and Long-term Sequelae - [266]
Krassas GE, Poppe K, Glinoer D. “Thyroid function and human reproductive health.” Endocrine reviews (2010). PMID: 20573783 ↗
L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [267]
Angermayr L, Clar C. “WITHDRAWN: Iodine supplementation for preventing iodine deficiency disorders in children.” The Cochrane database of systematic reviews (2018). PMID: 30489630 ↗
L1SR_OBSCited in: Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [268]
Osborn DA, Hunt RW. “Prophylactic postnatal thyroid hormones for prevention of morbidity and mortality in preterm infants.” The Cochrane database of systematic reviews (2007). PMID: 17253571 ↗
L1SR_OBSCited in: Complications and Long-term Sequelae - [269]
Sasaki T, Kihara M, Fujishima M et al.. “Markedly Elevated Preoperative Thyroid-Stimulating Hormone Levels and Greater Operative Difficulty in Graves' Disease: A Single-Center Cohort Study.” Thyroid : official journal of the American Thyroid Association (2026). PMID: 42126184 ↗
L3COHORTCited in: Complications and Long-term Sequelae - [270]
Song X, Hu Y, Chen Y. “Uterine fibroids detected in early pregnancy and their association with adverse pregnancy outcomes: a single-centre retrospective cohort study.” BMC pregnancy and childbirth (2026). PMID: 42026504 ↗
L3COHORTCited in: Complications and Long-term Sequelae - [271]
Xie Y, Chen B, Gao S et al.. “Perinatal Endocrine-Cardiac Axis: A Narrative Review of Long-Term Cardiovascular Risks in Women with Gestational Diabetes, Hypertensive Disorders, and Thyroid Dysfunction.” Biomedicines (2026). PMID: 42351750 ↗
L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae - [272]
Ettleson MD, Wan W, Laiteerapong N et al.. “A Longitudinal, Real-World Study of the Relationship between Levothyroxine Dose and Suboptimal Hypothyroidism Treatment.” Thyroid : official journal of the American Thyroid Association (2026). PMID: 42308153 ↗
L2OTHERCited in: Complications and Long-term Sequelae - [273]
Meneghini V, Beltrão FEL, Ismail A et al.. “Impact of Hypothyroidism on Short-Term and Long-Term Outcomes of Coronary Artery Bypass Graft Surgery.” Thyroid : official journal of the American Thyroid Association (2026). PMID: 42287021 ↗
L3OTHERCited in: Complications and Long-term Sequelae - [274]
Fetene DM, Betts KS, Alati R. “MECHANISMS IN ENDOCRINOLOGY: Maternal thyroid dysfunction during pregnancy and behavioural and psychiatric disorders of children: a systematic review.” European journal of endocrinology (2017). PMID: 28982961 ↗
L2SR_OBSCited in: Prognosis, Natural History, Special Populations and Prevention - [275]
Chen Z, Yildiz S, Markova B et al.. “3,3',5-Triiodothyroacetic Acid Transporters.” Thyroid : official journal of the American Thyroid Association (2024). PMID: 38836423 ↗
L5OTHERCited in: Prognosis, Natural History, Special Populations and Prevention - [276]
Sun F, Zhang JX, Yang CY et al.. “The genetic characteristics of congenital hypothyroidism in China by comprehensive screening of 21 candidate genes.” European journal of endocrinology (2018). PMID: 29650690 ↗
L4OTHERCited in: Prognosis, Natural History, Special Populations and Prevention - [277]
Azizi F, Amouzegar A. “Management of hyperthyroidism during pregnancy and lactation.” European journal of endocrinology (2011). PMID: 21389085 ↗
L5REVIEW_NARRATIVECited in: Prognosis, Natural History, Special Populations and Prevention - [278]
Zhang HY, Zhang CX, Wu FY et al.. “Large-scale screening and functional study of DUOXA2 variant in 599 Chinese patients with congenital hypothyroidism.” European journal of endocrinology (2025). PMID: 40510014 ↗
L4OTHERCited in: Prognosis, Natural History, Special Populations and Prevention - [279]
Coomarasamy A, Dhillon-Smith RK, Papadopoulou A et al.. “Recurrent miscarriage: evidence to accelerate action.” Lancet (London, England) (2021). PMID: 33915096 ↗
L1OTHERCited in: Prognosis, Natural History, Special Populations and Prevention - [280]
Liu L, Wang C, Chen X et al.. “Association Between MTHFR Gene Polymorphisms and Subclinical Hypothyroidism in Early Pregnancy: A Retrospective Case-Control Study.” International journal of women's health (2026). PMID: 42338702 ↗
L3CASE_CONTROLCited in: Prognosis, Natural History, Special Populations and Prevention - [281]
Wigh IMN, Karmisholt J, Vestergaard P et al.. “Maternal thyroid disease and the risk of excessive bleeding in pregnancy: a Danish nationwide cohort study.” Thyroid research (2026). PMID: 42218541 ↗
L2COHORTCited in: Prognosis, Natural History, Special Populations and Prevention